Research Article The Influence of Carrier Oils on the Antimicrobial Activity and Cytotoxicity of Essential Oils Ané Orchard,1 Guy Kamatou ,2 AlvaroM. Viljoen,2,3 Namita Patel,1 Patricia Mawela,1 and Sandy F. van Vuuren 1 1University of the Witwatersrand, Faculty of Health Sciences, Department of Pharmacy and Pharmacology, 7 York Road, Parktown 2193, South Africa 2Tshwane University of Technology, Faculty of Science, Department of Pharmaceutical Sciences, Private Bag X680, Pretoria 0001, South Africa 3SAMRC Herbal Drugs Research Unit, Department of Pharmaceutical Sciences, Private Bag X680, Pretoria 0001, South Africa Correspondence should be addressed to Sandy F. van Vuuren; sandy.vanvuuren@wits.ac.za Received 12 September 2018; Accepted 13 November 2018; Published 14 January 2019 Academic Editor: Gabriel A. Agbor Copyright © 2019 Ané Orchard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The topical use of essential oils requires dilution into a carrier oil; however, scientific evidence regarding the antimicrobial efficacy and cytotoxicity when a carrier oil is combined with an essential oil is lacking. This study sets out to determine the antimicrobial activity and cytotoxicity of 23 essential oils combined with six known carrier oils. Gas chromatography-mass spectrometry/flame ionization detector (GC-MS/FID) was used to characterize the methyl esters of the carrier oils. The antimicrobial activity of the carrier oils alone and in combination with the essential oils was investigated using the broth microdilution assay against 11 skin pathogens and the cytotoxicity was determined using the brine shrimp lethality assay. The interactive profiles of the combinations for both antimicrobial activity and the cytotoxicity were analysed and calculated using the fractional inhibitory concentration index (ΣFIC).The carrier oils demonstrated no antimicrobial antagonismwhen combined with the essential oils and the overall cytotoxicity of the majority of the combinations was decreased. The carrier oils that could be identified as enhancing the antimicrobial activity and decreasing the cytotoxicity were Aloe veraMill. and Simmondsia chinensis C.K.Schneid (Jojoba oil), with an overall reduction in essential oil cytotoxicity of 87.5% at 24 hrs and 85% at 48 hrs by A. vera. Five of the essential oils (when diluted in A. vera and S. chinensis carrier oils) demonstrated enhanced antimicrobial activity against pathogens such as Brevibacterium epidermidis, B. linens, and P. aeruginosa with MIC values ranging from 0.09 to 0.50 mg/mL (and ΣFIC 0.14-0.39). The study could conclude that the carrier oils are complementary to essential oil formulations, mostly reducing cytotoxicity and in some cases enhancing the antimicrobial activity. 1. Introduction Essential oils are popular in complementary medicine and often used to treat dermatological conditions. A common example is Melaleuca alternifolia Cheel. (tea tree), which is known worldwide as an anti-infective essential oil and is used in many commercial acne products. These products are considered as a “safe” alternative and a preferred holistic treatment by consumers, but what has not been considered is the common use with a carrier oil. Recent findings of the antimicrobial activity of essential oils against skin pathogens prompted further research into the combined usewith carrier oils [1, 2]. Essential oils are rarely used undiluted when applied directly to the skin [3]. Neat oils have been shown to cause skin irritation such as contact dermatitis [4]. They are thus blended into a base before application to the skin. This combination of essential oil and carrier oil not only dilutes the essential oils but also is believed to make the essential oils less toxic on the skin, slow down the evaporation rate, and increase essential oil absorption [3]. Increased absorption is achieved as carrier oils are composed of molecules which make them closely related to sebum (the skin’s own natural oil). Possible bases that essential oils can be diluted into include creams, gels, or carrier oils (also known as vegetable Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2019, Article ID 6981305, 24 pages https://doi.org/10.1155/2019/6981305 http://orcid.org/0000-0001-5518-9611 http://orcid.org/0000-0002-4859-1845 https://creativecommons.org/licenses/by/4.0/ https://doi.org/10.1155/2019/6981305 2 Evidence-Based Complementary and Alternative Medicine or fixed oils) [5]. It has, however, been found that a base can influence the overall antimicrobial activity of the oil [6]. Yet, there is a paucity of information relating to the effects of carrier oils on the antimicrobial activity and cytotoxicity of essential oils [7]; thus this study investigates this void with special emphasis on oils implicated in dermatology and interactions affecting skin pathogens. 2. Materials and Methods 2.1. Oil Selection. The selection of six carrier oils was based on the aroma-therapeutic literature available to the layman as reviewed by Orchard and van Vuuren [7], where the most frequently cited carrier oils for dermatological use and those claimed as having antimicrobial activity were selected. The selection of the 23 essential oils was made based on a range of activity, representative of noteworthy, moder- ate, and poor antimicrobial activity [1], so that an overall understanding could be drawn of carrier oil effects against different antimicrobial potencies. Consideration was also given to essential oils with poor activity, as, in combination, they may demonstrate synergy. Popular essential oils that are well known to the layman, such as M. alternifolia and Lavandula angustifolia Mill. (lavender), were also included (See supplementary data for selection (available here)). The carrier oils were obtained from Essentia. Essential oils were procured fromGivaudan (Dubendorf, Switzerland), Robertet (Grasse, France), Burgess and Finch, Prana Monde, Essentia, and Scatters Oils (all Gauteng, South Africa). 2.2. Chemical Analysis of the Carrier Oils. The chemical profiles of the essential oils have been previously investigated and reported [1]. The chemical characterization of the carrier oils required separation via the induction of volatility by methylating and conversion of the carrier oils into fatty acid methyl esters (FAMEs). This required the addition of 1.0 mL of hexane into 0.1 mL of the carrier oil. Thereafter, 1.0 mL sodium methoxide (1.6 g of NaOH in 50.0 mL of methanol) solution was added, and this mixture was vortexed for 30 s. This solution was then centrifuged at 1200 rpm and incubated at room temperature for 10 min to allow for the separation of the clear solution of FAMEs. The methyl esters were then transferred to a vial for analysis [8]. The FAME composition of each carrier oil was analysed by gas chromatography-mass spectrometry/flame ionization detec- tor (GC-MS/FID). The GC-MS/FID (Agilent 6860 N GC system) (Agilent Technologies, USA) was coupled directly to a 5973 mass selective detector (MSD) equipped with a 5% phenyl, polymethyl siloxane column (30 m× 250 mm i.d. × 0.25 �휇m film thickness). A volume of 1.0 �휇L was injected (using a split ratio of 1:50) with an autosampler at 24.79 psi and an inlet temperature of 250∘C.TheGC oven temperature was initially 60∘C for 10 min, rising to 250∘C at a rate of 4∘C/min. Helium was used as a carrier gas at a constant flow of 1.0 mL/min. Spectra were obtained on the electron impact at 70 eV, scanning from 35 to 450m/z.The percentage composition of the individual components was quantified by integration measurements using flame ionization detection (FID, 250∘C) while the identification was based on the total ion chromatogram (TIC) using ChemStation software. Com- ponent identification was made by using available FAMEs reference compounds in combination with library searching of the Mass Finder�, Flavor�, and NIST libraries [9]. 2.3. Preparation of Cultures. The 11 microorganisms tested were either from the American Type Culture Collec- tion (ATCC) or Deutsche Summlung von Mikrooganis- men (DSM) strains. The skin pathogens included reference strains of the wound pathogens Staphylococcus aureus ATCC 25923 (including two antibiotic resistant strains, methicillin resistant S. aureus (MRSA) ATCC 43300, and gentamicin- methicillin resistant S. aureus (GMRSA) ATCC 33592) and twoGram-negative bacteria (Pseudomonas aeruginosaATCC 27858, Escherichia coli ATCC 25922), odour inducing bac- teria (Brevibacterium agri ATCC 51663, B. epidermidis DSM 20660, B. linens DSM 20425), acne pathogens (S. epidermidis ATCC 2223, and Propionibacterium acnes ATCC 11827), and the yeastCandida albicansATCC 10231.Candida albicanswas inoculated into Tryptone Soya broth (TSB) (Oxoid) and incu- bated at 37∘C for 48 hrs.The fastidious pathogen, P. acneswas grown in Thioglycolate broth (TGB) (Oxoid) and incubated under anaerobic conditions using a CO2 incubator (8.4% CO2) for seven days at 37∘C. Brevibacterium linens required inoculation into TSB and incubation at 30∘C for four days, and the remaining bacterial cultures were also all inoculated into TSB for 24 hrs at 37∘C. All cultures were streaked onto Tryptone Soya agar (Oxoid) and incubated to confirm purity. TheUniversity of the Witwatersrand Human Research Ethics Committee (Reference W-CJ-131026-3) granted a waiver for the use of these microorganisms. 2.4. Minimum Inhibitory Concentration (MIC). The broth microdilution method was determined as being the preferred method for investigating carrier oil activity [7]. The carrier oils alone and in combination with essential oils were tested in 1:1 ratios using the broth microdilution assay as detailed in [2]. After the aseptic preparation of 100 �휇L of sterile, distilled water was added to each of the 96 wells of a microtitre plate, followed by 100 �휇L of the carrier oil, or 50 �휇L essential oil with 50 �휇L carrier oil for the combinations, to the first row. This was serially diluted descending down the microtitre plate columns. Antimicrobial susceptibility was confirmed with the inclusion of 0.01 mg/mL ciprofloxacin (Sigma Aldrich�) (for bacteria) or 0.10 mg/mL amphotericin B (Sigma Aldrich�) (for C. albicans). A negative control of 32.0 mg/mL water in acetone was included to ensure the antimicrobial activity was not as a result of the solvent. The respective growth media of each pathogen were also included to ensure the support of microbial growth. After the preparation of an approximate inoculum concentration of 1 × 106 colony forming units per mL (CFU mL−1) for each microorganism, 100 �휇L was added to each well. Sterile adhe- sive sealing film was used to seal eachmicrotitre plate and the plates were incubated accordingly. After incubation, 40 �휇L of 0.04% (w/v) p-iodonitrotetrazolium violet solution (INT) (Sigma Aldrich�) was added to each well. A colour change Evidence-Based Complementary and Alternative Medicine 3 of the indicator to pink or purple was indicative of microbial growth; thus the lowest concentration displaying no growth was taken as the minimum inhibitory concentration (MIC). Each sample and combination was tested in triplicate and the mean taken. The MIC values were recorded and, for the combinations, the fractional inhibitory concentration index (ΣFIC) was calculated [10]. The ΣFIC values of the combinations were calculated using the following equations: FIC (i) = Value of (a∗) combined with value of (b∗) Value of (a) independently FIC (ii) = Value of (b) combined with value of (a) Value of (b) independently (1) ∗where (a) is either the MIC value of the first essential oil in the combination and (b) is the MIC value of the carrier oil. The FIC index could then be calculated: ΣFIC = FIC (i) + FIC (ii). If ΣFIC for the combination was ≤ 0.5 synergy was indicated, a ΣFIC of > 0.5 and ≤ 1.0 is indicative of an additive interaction, > 1.0 - ≤ 4.0 indicated indifference, and > 4.0 indicated antagonism [10]. 2.5. Brine Shrimp Lethality Assay. The preparation of artifi- cial sea water was undertaken by dissolving 16 g of Tropic Marine� sea salt in 500 mL of sterile distilled water. Dried Artemia franciscana (brine shrimp) eggs (Ocean Nutrition�) (0.5 g) were added to the salt water and aerated with a rotary pump (Kiho). A constant source of warmth and light was providedwith a lamp (220–240V).The incubation of the eggs under these conditions was at 25∘C for 18-24 hrs. The cytotoxicity evaluation was conducted in 48-well microtitre plates, where 400 �휇L salt water containing 40-60 live brine shrimp was added to each well.The test samples at a concentration of 1.00mg/mL (carrier oils, essential oils, or the combination of both) was then added (400 �휇L) to each well in triplicate. To ensure that the artificial sea water supported the growth and survival of the brine shrimp by mimicking their natural environment, 32.0 g/L artificial sea water was included as a negative control, along with 2% dimethyl sulfoxide (DMSO), which was used as the solvent for the samples. Potassium dichromate (Sigma Aldrich), which is a known toxic compound, was used as a positive control at a concentration of 1.60 mg/mL. The plates were viewed after 24 and 48 hrs under a light microscope (Olympus) at 40×magnification and the dead brine shrimp counted. Each sample and combination was tested in triplicate and themean taken. A lethal dose of acetic acid (Saarchem; 100% (v/v); 50.0 �휇L)was thereafter added to eachwell and a final count of dead brine shrimp undertaken [11]. The percentage mortality was calculated using the following equation: % Mortality = dead shrimp at 24 hours (or 48 hours) (before acetic acid) − dead shrimp (time 0) dead shrimp (after acetic acid) × 100 (2) Biological cytotoxicity was considered for a percentage mor- tality of 50% or greater [12].The fractional inhibitory concen- tration index (ΣFIC) was calculated for the combinations to determine the overall effect off the carrier oils on the essential oil cytotoxicity. The ΣFIC ranges were classified as follows: synergy for values ≤ 0.5, where there is a substantial decrease in cytotoxicity, additive interactions for aΣFIC range between > 0.5 and ≤ 1.0, indifference for a ΣFIC range of between > 1.0 and ≤ 4.0, and > 4.0 indicated antagonism where an increase in cytotoxicity was observed for the combination. 3. Results and Discussion 3.1. Chemical Analysis. The chemical composition of the essential oils has been previously reported [1] and is included in Table 1. It is known that the chemical composition of essen- tial oils may vary due to differences in chemotype, storage, harvesting, or plant origin [13–15]. For example, the sample of �ymus vulgaris from this study has a lower content of thymol (18.9%) than reported in previous studies (44.7-48.9%) [16– 18] and the Laurus nobilis sample used in this study contains myrcene and chavicol, as opposed to high levels of 1,8-cineole (35.5-42.3%) as previously reported [19, 20]. Five out of the six carrier oils contained both linoleic acid and oleic acid methyl esters (Table 2). Aloe veraMill. (aloe vera), Calendula officinalis L. (calendula), and Hypericum perforatum L. (St John’s wort) are characterized by high levels of linoleic acid methyl ester (59.8-69.9%). Persea americana Mill. (avocado) and Prunus armeniaca Blanco (apricot kernel) are dominated by a high percentage of oleic acid, methyl ester (60.7-69.5%). Simmondsia chinensis C.K.Schneid (jojoba) was found to be different from the other carrier oils with eicosenoic acid (55.6%) being the major fatty acid.Aloe vera and P. americana oils also contained vitamin E. 3.2. Antimicrobial Activity. The antimicrobial activity of the essential oils has previously been reported [1].The carrier oils, overall, displayed poor antimicrobial activity (Table 2). The only bacterial species that was somewhat inhibited by the car- rier oils was P. aeruginosa and B. epidermidis at 1.00 mg/mL for selected carrier oils. The poor antimicrobial activity is not surprising as they are not expected to exhibit antimicrobial activity [7] but rather provide other properties against skin conditions such as anti-inflammatory, anti-oxidant, or an increase in collagen synthesis [7]. From an antimicrobial perspective, another two studies also reported poor antimi- crobial activity of S. chinensis [21].When studied in combina- tion, however, De Prijck, Peeters, and Nelis [21] reported an increase in antimicrobial activity of the S. chinensis carrier oil andM. alternifolia essential oil combination tested against E. 4 Evidence-Based Complementary and Alternative Medicine Table 1: Essential oil main compounds. Essential oil GC-MS FID∗ Cananga odorataHook.f. &Thomson (ylang ylang) Benzyl acetate (30.5%) Linalyl acetate (27.7%) Methyl benzoate (10.3%) Methylanisole (10.9%) Cinnamomum zeylanicum Blume (cinnamon leaf) Eugenol (78.4%) Citrus bergamia Risso (bergamot) Limonene (39.1%) Linalyl acetate (9.3%) Linalyl formate (33.0%) Citrus reticulata Blanco (mandarin) Limonene (93.8%) Commiphora myrrha Engl. (myrrh) Furanoeusdema-1,3-diene (52.9%) Lindestrene (15.8%) Cymbopogon citratus Stapf (lemongrass) Limonene (11.7%) Neral (28.9%) Geranial (42.7%) Cymbopogon martinii Stapf (palmarosa) Geraniol (80.7%) Eucalyptus globulus Labill. (eucalyptus) 1,8-Cineole (63.6%) �훼-Terpineol (10.5%) Helichrysum italicum (Roth) G.Don (immortelle) �훽-Pinene (7.6%) 1,8-Cineole (19.4%) �훽-Caryophyllene (12.4%) �훼-Humulene (15.0%) Kunzea ericoides (A.Rich.) JoyThomps. (kanuka) �훼-Pinene (52.9%) p-Cymene (11.9%) Laurus nobilis L. (bay) Eugenol (54.4%) Myrcene (18.5%) Chavicol (11.5%) Lavandula angustifolia Mill. (lavender) Linalyl acetate (35.6%) Linalool (32.8%) �훽-Caryophyllene (10.2%) Leptospermum scoparium J.R.Forst. and G.Forst (manuka) Neral (23.0%) Geranial (35.0%) Citronellol (15.4%) Litsea cubeba Pers. (may chang) Geranial (44.6%) Neral (28.8%) Melaleuca alternifolia Cheel (tea tree) �훾-Terpinene (16.6%) p-Cymene (9.6%) Terpinen-4-ol (44.6%) Melaleuca viridiflora Gaertn. (niaouli) Linalyl acetate (49.8%) Linalool (30.1%) Melissa officinalis L. (lemon balm) Citronellal (35.6%) Neral (7.1%) Terpinyl acetate (14.2%) �훼-Terpineol (7.3%) Geranial (8.4%) cis-Geraniol (7.2%) Pogostemon patchouli Benth. (patchouli) �훽-Patchoulene (38.3%) �훼-Bulnesene (13.0%) �훼-Guaiene (11.9%) Evidence-Based Complementary and Alternative Medicine 5 Table 1: Continued. Essential oil GC-MS FID∗ Santalum album L. (sandalwood) �훼-Santalol (32.1%) cis-�훼-Santalol (11.3%) 4,5,9,10-Dehydroisolongifolene (12.3%) Styrax benzoin Dryand. (benzoin) Benzyl acetate (7.2%) Ethyl cinnamate (5.7%) Dimethyl phthalate (72.2%) Syzygium aromaticum (L.) Merr. & L.M.Perry (clove) Eugenol (81.9%) Isoeugenol (13.1%) �ymus vulgaris L. (thyme) Thymol (18.9%) �훾-Terpinene (7.2%) p-Cymene (41.0%) Vetiveria zizanioides Stapf (vetiver) �훽-Vetirenene (8.8%) Zizanol (12.8%) ∗Previously reported in Orchard, Sandasi, Kamatou, Viljoen, and van Vuuren [1] 0 5 10 15 20 25 B. ag ri B. ep iderm idis B. lin ens S. a ureu s MRSA GMRSA S. e pid erm idis P. a cnes E. co li P. a eru gin osa C. al bic an s A. vera C. officinalis H. perforatum P. americana P. armeniaca S. chinensis N um be r o f n ot ew or th y co m bi na tio ns Figure 1: Summary of the antimicrobial activity of essential oil: carrier oil combinations activity. coli, S. aureus, and P. aeruginosa. Unfortunately, the diffusion assay was utilised, making comparison with the current study difficult and somewhat inaccurate due to the inherent flaws associated with oils and agar diffusion assays. This study, however, could report on moderate antimicrobial activity (2.00 mg/mL) for this combination. This is the first study to report on S. chinensis against MRSA, GMRSA, acne, and bromodosis pathogens. Aloe vera gel has been reported to display antimicrobial activity [14]. The antimicrobial activity of the carrier oil, however, is reported for the first time in this study. As with this study, P. armeniaca has also previously been reported to display poor antimicrobial activity (>2.00% v/v) against E. coli, P. aeruginosa, S. aureus, and H. perforatum was previously shown to display poor to no antimicrobial activity against S. aureus [15]. However, to the best of our knowledge, the antimicrobial activity of C. officinalis and P. americana carrier oils are reported here for the first time against all 11 pathogens. Although not expected to display antimicrobial activity, the observed antimicrobial activity of the carrier oils may likely be attributed to the free fatty acids, such as linoleic acid and oleic acids, which individually have displayed antimicrobial activity against the Gram-positive micro-organisms such as P. acnes and S. aureus at high concentrations [16]. The antimicrobial activity of the essential oils combined with the carrier oils (1518 combinations consisting of 23 essential oils combined with six different carrier oils, against 11 pathogens involved in skin infections), alongwith the inter- active profiles of the combinations, is displayed in Table 3. Figure 1 summarises the antimicrobial activity of the essential oils combined with each carrier oil, and Figure 2 summarises the interactive profiles of all the studied combinations. The majority of the combinations were found to be additive (52.2%), and 45.8% were found to be indifferent. Synergy was also identified in 30 combinations, and, encouragingly, 6 Evidence-Based Complementary and Alternative Medicine Ta bl e 2: A nt im ic ro bi al ac tiv ity ,c yt ot ox ic ity an d fa tty ac id co m po sit io n of ca rr ie ro ils . C ar ri er oi l Fa tty ac id co m po si tio n A nt im ic ro bi al ac tiv ity (m g/ m L) Cy to to xi ci ty (% m or ta lit y) P. ac ne s AT C C 11 82 7 S. ep i AT C C 22 23 S. au re us AT C C 25 92 4 M RS A AT C C 43 30 0 G M RS A AT C C 33 59 2 E. co li AT C C 87 39 P. ae ru g AT C C 27 85 8 B. ag ri AT C C 51 66 3 B. ep i D SM 20 66 0 B. lin D SM 20 42 5 C. al b AT C C 10 23 1 24 hr s 48 hr s Al oe ve ra (a lo e ve ra ) lin ol ei ca ci d m et hy le ste r( 59 .8 % ) 16 .0 0 16 .0 0 10 .0 0 8. 00 4. 00 8. 00 1.0 0 2. 00 1.0 0 8. 00 8. 00 0. 00 27 .0 8 ol ei ca ci d, m et hy le ste r( 23 .0 % ) pa lm iti ca ci d m et hy le ste r( 8. 9% ) ste ar ic ac id m et hy le ste r( 4. 2% ) lin ol en ic ac id m et hy le ste r( 3. 7% ) Vi ta m in E -1 4 IU 46 % Ca len du la offi cin al is (c al en du la ) lin ol ei ca ci d m et hy le ste r( 66 .8 % ) 3. 00 16 .0 0 4. 00 5. 60 7.0 0 4. 00 1.5 0 2. 00 2. 00 8. 00 16 .0 0 0. 00 28 .3 5 ol ei ca ci d, m et hy le ste r( 24 .6 % ) pa lm iti ca ci d m et hy le ste r( 14 .9 % ) lin ol en ic ac id m et hy le ste r( 1.0 % ) H yp er icu m pe rfo ra tu m (S t Jo hn ’s wo rt ) lin ol ei ca ci d m et hy le ste r( 69 .9 % ) 2. 50 16 .0 0 4. 00 4. 00 4. 00 4. 00 1.5 0 2. 00 1.0 0 2. 00 4. 00 0. 63 39 .33 ol ei ca ci d, m et hy le ste r( 19 .0 % ) ste ar ic ac id m et hy le ste r( 5. 0% ) pa lm iti ca ci d m et hy le ste r( 5. 8% ) lin ol en ic ac id m et hy le ste r( 0. 1% ) Pe rs ea am er ica na (a va ca do ) ol ei ca ci d, m et hy le ste r( 69 .5 % ) 8. 00 16 .0 0 4. 00 5. 20 4. 00 4. 00 1.7 5 2. 00 4. 00 8. 00 16 .0 0 0. 00 25 .7 5 pa lm iti ca ci d m et hy le ste r( 14 .9 % ) lin ol ei ca ci d m et hy le ste r( 9.2 % ) pa lm ito le ic ac id m et hy le ste r( 5. 5% ) lin ol en ic ac id m et hy le ste r( 0. 6% ) Pr un us ar m en ia ca (a pr ic ot ke rn el ) ol ei ca ci d, m et hy le ste r( 60 .7 % ) 8. 00 6. 00 2. 00 4. 00 2. 00 4. 00 1.0 0 2. 00 1.0 0 6. 00 8. 00 4. 35 10 .3 8 lin ol ei ca ci d m et hy le ste r( 27 .0 % ) pa lm iti ca ci d m et hy le ste r( 5. 7% ) pa lm ito le ic ac id m et hy le ste r( 4. 7% ) ste ar ic ac id m et hy le ste r( 0. 9% ) Vi ta m in E 13 .2 m g/ 10 0g Si m m on ds ia ch in en sis (jo jo ba ) 11- ei co se no ic ac id ,m et hy le ste r (5 5. 6% ) 1.5 0 16 .0 0 4. 00 4. 00 4. 00 4. 00 1.0 0 2. 00 1.0 0 2. 00 6. 00 3. 04 24 .12 pa lm iti ca ci d m et hy le ste r( 15 .9 % ) Evidence-Based Complementary and Alternative Medicine 7 Ta bl e 2: C on tin ue d. C ar ri er oi l Fa tty ac id co m po si tio n A nt im ic ro bi al ac tiv ity (m g/ m L) Cy to to xi ci ty (% m or ta lit y) P. ac ne s AT C C 11 82 7 S. ep i AT C C 22 23 S. au re us AT C C 25 92 4 M RS A AT C C 43 30 0 G M RS A AT C C 33 59 2 E. co li AT C C 87 39 P. ae ru g AT C C 27 85 8 B. ag ri AT C C 51 66 3 B. ep i D SM 20 66 0 B. lin D SM 20 42 5 C. al b AT C C 10 23 1 24 hr s 48 hr s A nt im ic ro bi al co nt ro ls ci pr ofl ox ac in �휇 g/ m L 0. 78 x 10 − 3 0. 25 x 10 − 3 0. 5 x 10 − 3 0. 78 x 10 − 3 0. 31 x 10 − 3 0. 08 x 10 − 3 0. 31 x 10 − 3 0. 16 x 10 − 3 0. 26 x 10 − 3 0. 63 x 10 − 3 n. a am ph ot er ic in �휇 g/ m L ∗ n. a n. a n. a n. a n. a n. a n. a n. a n. a n. a 6. 25 x 10 − 3 D M SO m g/ m L 5. 26 19 .3 4 Se aw at er m g/ m L 10 .7 5 32 .7 2 Po ta ss iu m di ch ro m at e m g/ m L 99 .4 4 10 0. 00 ∗ n. a., no ta pp lic ab le .S .e pi :S .e pi de rm id is; P. ae ru g: P. ae ru gi no sa ;B .e pi :B .e pi de rm id is; B. lin :B .l in en s; C. al b: C. al bi ca ns . 8 Evidence-Based Complementary and Alternative Medicine Ta bl e 3: A nt im ic ro bi al ac tiv ity (m g/ m L) of es se nt ia lo ils co m bi ne d w ith ca rr ie ro ils ag ai ns ts ki n pa th og en s. B. ag ri AT C C 51 66 3 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 0. 50 1 .0 0 ∗ 1.2 5 1.0 0 1.2 5 2. 00 2. 50 1.0 0 1.2 5 1.0 0 1.2 5 1.0 0 1.2 5 Ci nn am om um ze yl an icu m (c in na m on ) 0. 50 1.0 0 1.2 5 1.0 0 1.2 5 0. 50 0. 63 0. 50 0. 63 1.0 0 1.2 5 1.0 0 1.2 5 Ci tru sb er ga m ia (b er ga m ot ) 1.0 0 2. 00 1.5 0 1.0 0 0. 75 2. 00 1.5 0 1.0 0 0. 75 2. 00 1.5 0 2. 00 1.5 0 Ci tru sr et icu la ta (m an da rin ) 1.0 0 1.0 0 0. 75 1.0 0 0. 75 1.0 0 0. 75 0. 50 0. 38 † 1.0 0 0. 75 1.5 0 1.1 3 Co m m ip ho ra m yr rh a (m yr rh ) 0. 38 0. 38 0. 60 0. 44 0. 69 0. 38 0. 60 0. 38 0. 60 0. 50 0. 78 0. 35 0. 55 Cy m bo po go n cit ra tu s (le m on gr as s) 0. 25 1.0 0 2. 25 0. 50 1.1 3 0. 50 1.1 3 0. 50 1.1 3 0. 50 1.1 3 0. 50 1.1 3 Cy m bo po go n m ar tin ii (p al m ar os a) 0. 38 1.0 0 1.5 7 0. 50 0. 78 0. 50 0. 78 0. 33 0. 52 0. 75 1.1 7 1.0 0 1.5 7 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 0. 50 2. 00 2. 50 1.5 0 1.8 8 1.0 0 1.2 5 2. 00 2. 50 1.0 0 1.2 5 2. 00 2. 50 H eli ch ry su m ita lic um (im m or te lle ) 0. 50 1.0 0 1.2 5 1.0 0 1.2 5 1.0 0 1.2 5 0. 7 5 0. 94 1.0 0 1.2 5 1.0 0 1.2 5 Ku nz ea er ico id es (k an uk a) 1.0 0 2. 00 1.5 0 1.0 0 0. 75 2. 00 1.5 0 1.0 0 0. 75 2. 00 1.5 0 2. 00 1.5 0 La ur us no bi lis (b ay ) 0. 50 1.0 0 1.2 5 0. 50 0. 63 1.0 0 1.2 5 0. 50 0. 63 1.0 0 1.2 5 0. 50 0. 63 La va nd ul a an gu sti fo lia (la ve nd er ) 1.0 0 1.5 0 1.1 3 1.0 0 0. 75 1.0 0 0. 75 1.0 0 0. 75 1.5 0 1.1 3 2. 00 1.5 0 Le pt os pe rm um sc op ar iu m (m an uk a) 0. 38 0. 50 0. 78 0. 50 0. 78 0. 50 0. 78 0. 50 0. 78 0. 50 0. 78 0. 50 0. 78 Li tse a cu be ba (m ay ch an g) 0. 13 0. 80 3. 28 0. 50 2. 05 0. 50 2. 05 0. 50 2. 05 0. 50 2. 05 0. 75 3. 07 M ela leu ca al te rn ifo lia (te at re e) 1.0 0 1.5 0 1.1 3 1.0 0 0. 75 1.0 0 0. 75 1.0 0 0. 75 1.0 0 0. 75 1.5 0 1.1 3 M ela leu ca vi rid ifl or a (n ia ou li) 1.0 0 3. 00 2. 25 1.0 0 0. 75 2. 00 1.5 0 1.0 0 0. 75 2. 00 1.5 0 1.0 0 0. 75 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 1.0 0 0. 75 0. 75 0. 56 1.0 0 0. 75 0. 50 0. 38 1.0 0 0. 75 1.0 0 0. 7 5 Po go ste m on pa tch ou li (p at ch ou li) 0. 09 0. 60 3. 48 0. 19 1.1 0 0. 13 0. 73 0. 25 1.4 5 0. 60 3. 48 0. 50 2. 90 Sa nt al um al bu m (s an da lw oo d) 0. 31 0. 38 0. 70 0. 31 0. 58 0. 30 0. 56 0. 31 0. 58 0. 31 0. 58 0. 31 0. 58 St yr ax be nz oi n (b en zo in ) 0. 50 1.0 0 1.2 5 1.0 0 1.2 5 1.0 0 1.2 5 1.0 0 1.2 5 1.5 0 1.8 8 1.0 0 1.2 5 Sy zy giu m ar om at icu m (c lo ve ) 0. 50 1.0 0 1.2 5 1.0 0 1.2 5 0. 75 0. 94 0. 50 0. 63 0. 75 0. 94 1.0 0 1.2 5 � ym us vu lga ris (th ym e) 0. 50 2. 00 2. 50 1.0 0 1.2 5 1.0 0 1.2 5 1.0 0 1.2 5 1.0 0 1.2 5 1.0 0 1.2 5 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 05 0. 25 2. 56 0. 25 2. 56 0. 25 2. 56 0. 25 2. 56 0. 38 3. 84 0. 25 2. 56 Evidence-Based Complementary and Alternative Medicine 9 Ta bl e 3: C on tin ue d. B. ep id er m id is D SM 20 66 0 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 0. 50 0. 50 0. 75 1.0 0 1.2 5 0. 50 0. 75 1.0 0 1.1 3 0. 50 0. 75 0. 13 0. 19 Ci nn am om um ze yl an icu m (c in na m on ) 1.5 0 0. 75 0. 63 1.0 0 0. 58 0. 75 0. 63 1.2 0 0. 55 0. 75 0. 63 0. 75 0. 63 Ci tru sb er ga m ia (b er ga m ot ) 0. 50 0. 50 0. 75 1.0 0 1.2 5 1.0 0 1.5 0 1.0 0 1.1 3 0. 50 0. 75 0. 75 1.1 3 Ci tru sr et icu la ta (m an da rin ) 1.5 0 1.0 0 0. 83 2. 00 1.1 7 0. 75 0. 63 2. 00 0. 92 0. 75 0. 63 0. 75 0. 63 Co m m ip ho ra m yr rh a (m yr rh ) 0. 25 0. 25 0. 63 0. 75 1.6 9 0. 25 0. 63 0. 50 1.0 6 0. 25 0. 63 0. 25 0. 63 Cy m bo po go n cit ra tu s (le m on gr as s) 0. 50 0. 50 0. 75 1.0 0 1.2 5 0. 50 0. 75 1.0 0 1.1 3 0. 50 0. 75 0. 50 0. 75 Cy m bo po go n m ar tin ii (p al m ar os a) 0. 50 1.0 0 1.5 0 1.0 0 1.2 5 0. 50 0. 75 1.0 0 1.1 3 0. 50 0. 75 0. 50 0. 75 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 0. 50 2. 00 3. 00 2. 00 2. 50 1.0 0 1.5 0 0. 25 0. 28 2. 50 3. 75 2. 00 3. 00 H eli ch ry su m ita lic um (im m or te lle ) 0. 50 0. 50 0. 75 2. 00 2. 50 0. 50 0. 75 1.0 0 1.1 3 0. 50 0. 75 0. 50 0. 75 Ku nz ea er ico id es (k an uk a) 1.0 0 0. 75 0. 75 1.0 0 0. 75 0. 75 0. 75 1.0 0 0. 63 0. 75 0. 75 0. 75 0. 75 La ur us no bi lis (b ay ) 0. 25 0. 38 0. 94 0. 50 1.1 3 0. 50 1.2 5 0. 50 1.0 6 0. 50 1.2 5 0. 50 1.2 5 La va nd ul a an gu sti fo lia (la ve nd er ) 1.0 0 0. 75 0. 75 1.0 0 0. 75 0. 75 0. 75 1.0 0 0. 63 0. 75 0. 75 0. 75 0. 75 Le pt os pe rm um sc op ar iu m (m an uk a) 1.0 0 0. 75 0. 75 1.0 0 0. 75 0. 75 0. 75 1.0 0 0. 63 0. 75 0. 75 0. 75 0. 75 Li tse a cu be ba (m ay ch an g) 1.0 0 0. 75 0. 75 1.0 0 0. 75 0. 75 0. 75 2. 00 1.2 5 0. 75 0. 75 1.0 0 1.0 0 M ela leu ca al te rn ifo lia (te at re e) 0. 50 1.0 0 1.5 0 1.0 0 1.2 5 1.0 0 1.5 0 1.0 0 1.1 3 2. 00 3. 00 1.0 0 1.5 0 M ela leu ca vi rid ifl or a (n ia ou li) 1.0 0 0. 75 0. 75 1.0 0 0. 75 0. 75 0. 75 1.0 0 0. 6 3 0. 75 0. 75 0. 75 0. 75 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 0. 75 0. 75 1.5 0 1.1 3 0. 75 0. 75 1.0 0 0. 63 0. 75 0. 75 0. 75 0. 75 Po go ste m on pa tch ou li (p at ch ou li) 0. 50 0. 09 0. 14 1.0 0 1.2 5 0. 50 0. 75 1.0 0 1.1 3 0. 50 0. 75 0. 40 0. 60 Sa nt al um al bu m (s an da lw oo d) 0. 25 0. 25 0. 63 0. 25 0. 56 0. 25 0. 63 0. 25 0. 53 0. 25 0. 63 0. 25 0. 63 St yr ax be nz oi n (b en zo in ) 0. 50 0. 50 0. 75 1.0 0 1.2 5 0. 50 0. 75 1.0 0 1.1 3 0. 50 0. 75 0. 50 0. 75 Sy zy giu m ar om at icu m (c lo ve ) 0. 38 0. 50 0. 91 0. 50 0. 78 0. 50 0. 91 0. 50 0. 72 0. 50 0. 91 0. 50 0. 91 � ym us vu lga ris (th ym e) 0. 50 0. 50 0. 75 1.0 0 1.2 5 0. 50 0. 75 1.0 0 1.1 3 1.0 0 1.5 0 0. 50 0. 75 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 19 0. 19 0. 60 0. 50 1.4 4 0. 19 0. 60 0. 50 1.3 8 0. 25 0. 78 0. 19 0. 60 10 Evidence-Based Complementary and Alternative Medicine Ta bl e 3: C on tin ue d. B. lin en sD SM 20 42 5 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 1.0 0 1.0 0 0. 56 1.0 0 0. 56 0. 75 0. 56 1.5 0 0. 84 1.0 0 0. 58 1.0 0 0. 75 Ci nn am om um ze yl an icu m (c in na m on ) 0. 50 1.0 0 1.0 6 1.0 0 1.0 6 0. 45 0. 56 0. 50 0. 53 0. 50 0. 54 0. 75 0. 94 Ci tru sb er ga m ia (b er ga m ot ) 2. 00 0. 50 0. 16 1.7 0 0. 53 1.1 0 0. 55 1.7 5 0. 55 1.7 5 0. 58 1.2 0 0. 60 Ci tru sr et icu la ta (m an da rin ) 1.0 0 1.0 0 0. 56 1.0 0 0. 56 1.0 0 0. 75 2. 00 1.1 3 1.0 0 0. 58 0. 75 0. 56 Co m m ip ho ra m yr rh a (m yr rh ) 0. 38 0. 50 0. 69 0. 38 0. 52 0. 38 0. 60 0. 38 0. 52 0. 38 0. 52 0. 38 0. 60 Cy m bo po go n cit ra tu s (le m on gr as s) 0. 50 0. 50 0. 53 1.0 0 1.0 6 0. 50 0. 63 0. 50 0. 53 0. 50 0. 54 0. 45 0. 56 Cy m bo po go n m ar tin ii (p al m ar os a) 0. 75 0. 75 0. 55 1.0 0 0. 73 0. 60 0. 55 1.0 0 0. 73 0. 75 0. 56 0. 75 0. 69 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 1.0 0 1.0 0 0. 56 2. 00 1.1 3 1.0 0 0. 75 1.0 0 0. 56 1.0 0 0. 58 1.0 0 0. 75 H eli ch ry su m ita lic um (im m or te lle ) 0. 50 0. 50 0. 53 1.0 0 1.0 6 0. 50 0. 6 3 1.0 0 1.0 6 0. 50 0. 54 0. 63 0. 78 Ku nz ea er ico id es (k an uk a) 2. 00 0. 50 0. 16 1.7 5 0. 55 1.5 0 0. 75 1.7 5 0. 55 2. 00 0. 67 1.2 5 0. 63 La ur us no bi lis (b ay ) 0. 50 0. 50 0. 53 0. 75 0. 80 1.0 0 1.2 5 0. 50 0. 53 0. 75 0. 81 0. 50 0. 63 La va nd ul a an gu sti fo lia (la ve nd er ) 1.0 0 1.0 0 0. 56 1.0 0 0. 56 1.1 7 0. 88 1.0 0 0. 56 2. 00 1.1 7 1.0 0 0. 75 Le pt os pe rm um sc op ar iu m (m an uk a) 0. 50 0. 75 0. 80 1.0 0 1.0 6 0. 50 0. 63 1.0 0 1.0 6 0. 63 0. 68 0. 63 0. 78 Li tse a cu be ba (m ay ch an g) 0. 50 1.0 0 1.0 6 1.0 0 1.0 6 0. 50 0. 63 1.0 0 1.0 6 0. 50 0. 54 1.0 0 1.2 5 M ela leu ca al te rn ifo lia (te at re e) 1.5 0 1.5 0 0. 59 1.5 0 0. 59 1.0 0 0. 58 1.3 0 0. 51 1.5 0 0. 63 1.0 0 0. 58 M ela leu ca vi rid ifl or a (n ia ou li) 1.0 0 1.0 0 0. 56 1.0 0 0. 56 0. 75 0. 56 1.0 0 0. 56 1.0 0 0. 58 0. 75 0. 56 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 1.0 0 0. 56 1.0 0 0. 56 1.5 0 1.1 3 1.0 0 0. 56 1.2 5 0. 73 0. 75 0. 56 Po go ste m on pa tch ou li (p at ch ou li) 0. 75 0. 75 0. 55 0. 75 0. 55 0. 7 5 0. 69 0. 7 5 0. 55 0. 75 0. 56 0. 75 0. 69 Sa nt al um al bu m (s an da lw oo d) 0. 25 0. 50 1.0 3 0. 25 0. 52 0. 50 1.1 3 0. 25 0. 52 0. 50 1.0 4 0. 50 1.1 3 St yr ax be nz oi n (b en zo in ) 0. 75 0. 25 0. 18 1.0 0 0. 73 0. 75 0. 69 0. 75 0. 55 0. 75 0. 56 0. 63 0. 57 Sy zy giu m ar om at icu m (c lo ve ) 0. 50 0. 50 0. 53 0. 75 0. 80 0. 50 0. 63 1.0 0 1.0 6 0. 50 0. 54 0. 50 0. 63 � ym us vu lga ris (th ym e) 1.0 0 1.0 0 0. 56 1.0 0 0. 56 1.5 0 1.1 3 1.0 0 0. 56 1.5 0 0. 88 0. 75 0. 56 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 19 1.0 0 2. 69 0. 50 1.3 5 0. 33 0. 96 0. 50 1.3 5 0. 50 1.3 6 0. 19 0. 54 Evidence-Based Complementary and Alternative Medicine 11 Ta bl e 3: C on tin ue d. S. au re us AT C C 25 92 4 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 2. 00 2. 00 0. 60 2. 00 0. 75 2. 00 0. 75 2. 00 0. 75 2. 00 1.0 0 2. 00 0. 75 Ci nn am om um ze yl an icu m (c in na m on ) 0. 75 1.0 0 0. 72 1.0 0 0. 79 1.0 0 0. 79 1.0 0 0. 79 1.0 0 0. 92 1.0 0 0. 79 Ci tru sb er ga m ia (b er ga m ot ) 2. 00 2. 00 0. 60 2. 00 0. 75 2. 00 0. 75 2. 00 0. 75 2. 00 1.0 0 3. 00 1.1 3 Ci tru sr et icu la ta (m an da rin ) 2. 00 2. 67 0. 80 3. 00 1.1 3 2. 00 0. 75 4. 00 1.5 0 2. 00 1.0 0 2. 00 0. 75 Co m m ip ho ra m yr rh a (m yr rh ) 1.0 0 1.0 0 0. 55 1.0 0 0. 63 1.0 0 0. 63 1.0 0 0. 63 1.0 0 0. 75 1.0 0 0. 63 Cy m bo po go n cit ra tu s (le m on gr as s) 1.0 0 1.0 0 0. 55 1.0 0 0. 63 2. 00 1.2 5 1.0 0 0. 63 1.0 0 0. 75 1.0 0 0. 63 Cy m bo po go n m ar tin ii (p al m ar os a) 0. 50 1.5 0 1.5 8 1.0 0 1.1 3 1.5 0 1.6 9 1.0 0 1.1 3 1.0 0 1.2 5 2. 00 2. 25 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 2. 00 4. 00 1.2 0 8. 00 3. 00 2. 00 0. 75 8. 00 3. 00 4. 00 2. 00 5. 00 1.8 8 H eli ch ry su m ita lic um (im m or te lle ) 1.0 0 2. 00 1.1 0 3. 00 1.8 8 2. 00 1.2 5 3. 00 1.8 8 2. 00 1.5 0 2. 00 1.2 5 Ku nz ea er ico id es (k an uk a) 2. 00 2. 00 0. 60 2. 00 0. 75 2. 00 0. 75 2. 00 0. 75 5. 00 2. 50 2. 00 0. 75 La ur us no bi lis (b ay ) 1.0 0 1.0 0 0. 55 1.0 0 0. 63 1.0 0 0. 63 1.0 0 0. 63 2. 00 1.5 0 1.0 0 0. 63 La va nd ul a an gu sti fo lia (la ve nd er ) 4. 00 3. 00 0. 53 2. 50 0. 63 2. 50 0. 63 4. 00 1.0 0 2. 00 0. 75 2. 50 0. 63 Le pt os pe rm um sc op ar iu m (m an uk a) 1.0 0 1.0 0 0. 55 1.0 0 0. 63 1.0 0 0. 63 1.0 0 0. 63 1.0 0 0. 75 1.0 0 0. 63 Li tse a cu be ba (m ay ch an g) 1.0 0 1.0 0 0. 55 1.0 0 0. 63 1.5 0 0. 94 1.0 0 0. 63 1.0 0 0. 7 5 1.0 0 0. 6 3 M ela leu ca al te rn ifo lia (te at re e) 2. 00 2. 00 0. 60 2. 00 0. 75 3. 00 1.1 3 2. 00 0. 75 2. 00 1.0 0 2. 00 0. 75 M ela leu ca vi rid ifl or a (n ia ou li) 1.0 0 2. 00 1.1 0 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.5 0 2. 00 1.2 5 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 2. 00 1.1 0 2. 00 1.2 5 3. 00 1.8 8 2. 00 1.2 5 2. 00 1.5 0 2. 00 1.2 5 Po go ste m on pa tch ou li (p at ch ou li) 0. 50 2. 00 2. 10 1.0 0 1.1 3 2. 00 2. 25 1.5 0 1.6 9 2. 00 2. 50 1.0 0 1.1 3 Sa nt al um al bu m (s an da lw oo d) 0. 50 0. 50 0. 53 0. 50 0. 56 0. 50 0. 56 0. 50 0. 56 1.0 0 1.2 5 0. 50 0. 56 St yr ax be nz oi n (b en zo in ) 1.0 0 2. 00 1.1 0 2. 00 1.2 5 1.0 0 0. 63 2. 00 1.2 5 2. 00 1.5 0 2. 00 1.2 5 Sy zy giu m ar om at icu m (c lo ve ) 0. 88 1.5 0 0. 93 1.5 0 1.0 4 1.0 0 0. 69 1.0 0 0. 69 1.5 0 1.2 3 1.0 0 0. 69 � ym us vu lga ris (th ym e) 1.0 0 2. 00 1.1 0 2. 00 1.2 5 3. 00 1.8 8 2. 00 1.2 5 4. 00 3. 00 2. 00 1.2 5 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 50 0. 75 0. 79 0. 50 0. 56 1.0 0 1.1 3 0. 50 0. 56 1.0 0 1.2 5 0. 50 0. 56 12 Evidence-Based Complementary and Alternative Medicine Ta bl e 3: C on tin ue d. M RS A AT C C 43 30 0 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 4. 00 3. 00 0. 56 4. 00 0. 86 3. 00 0. 75 4. 00 0. 88 2. 50 0. 63 3. 00 0. 75 Ci nn am om um ze yl an icu m (c in na m on ) 1.5 0 2. 00 0. 79 2. 00 0. 85 2. 00 0. 92 2. 00 0. 86 2. 00 0. 92 1.2 0 0. 55 Ci tru sb er ga m ia (b er ga m ot ) 4. 00 4. 00 0. 75 4. 00 0. 86 2. 50 0. 63 8. 00 1.7 7 4. 00 1.0 0 4. 00 1.0 0 Ci tru sr et icu la ta (m an da rin ) 4. 00 6. 00 1.1 3 4. 00 0. 86 6. 00 1.5 0 4. 00 0. 88 8. 00 2. 00 4. 00 1.0 0 Co m m ip ho ra m yr rh a (m yr rh ) 0. 50 1.0 0 1.0 6 1.0 0 1.0 9 1.0 0 1.1 3 1.0 0 1.1 0 1.0 0 1.1 3 1.0 0 1.1 3 Cy m bo po go n cit ra tu s (le m on gr as s) 1.0 0 2. 00 1.1 3 2. 00 1.1 8 1.0 0 0. 63 1.0 0 0. 60 2. 00 1.2 5 1.0 0 0. 63 Cy m bo po go n m ar tin ii (p al m ar os a) 1.5 0 2. 00 0. 79 2. 00 0. 85 1.5 0 0. 69 3. 00 1.2 9 2. 00 0. 92 1.5 0 0. 69 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 2. 00 6. 00 1.8 8 8. 00 2. 71 4. 00 1.5 0 8. 00 2. 77 4. 00 1.5 0 4. 00 1.5 0 H eli ch ry su m ita lic um (im m or te lle ) 2. 00 4. 00 1.2 5 6. 00 2. 04 3. 00 1.1 3 3. 00 1.0 4 5. 00 1.8 8 4. 00 1.5 0 Ku nz ea er ico id es (k an uk a) 5. 00 4. 00 0. 65 4. 00 0. 76 4. 00 0. 90 3. 00 0. 59 4. 00 0. 90 3. 00 0. 68 La ur us no bi lis (b ay ) 1.0 0 2. 00 1.1 3 2. 00 1.1 8 2. 00 1.2 5 2. 00 1.1 9 2. 00 1.2 5 1.0 0 0. 63 La va nd ul a an gu sti fo lia (la ve nd er ) 2. 00 4. 00 1.2 5 4. 00 1.3 6 4. 00 1.5 0 4. 00 1.3 8 4. 00 1.5 0 4. 00 1.5 0 Le pt os pe rm um sc op ar iu m (m an uk a) 1.0 0 2. 00 1.1 3 3. 00 1.7 7 1.0 0 0. 63 2. 00 1.1 9 1.5 0 0. 94 1.0 0 0. 63 Li tse a cu be ba (m ay ch an g) 0. 50 1.0 0 1.0 6 1.0 0 1.0 9 1.0 0 1.1 3 2. 00 2. 19 1.0 0 1.1 3 1.0 0 1.1 3 M ela leu ca al te rn ifo lia (te at re e) 2. 00 3. 00 0. 94 4. 00 1.3 6 2. 00 0. 75 4. 00 1.3 8 4. 00 1.5 0 2. 00 0. 75 M ela leu ca vi rid ifl or a (n ia ou li) 2. 00 4. 00 1.2 5 4. 00 1.3 6 4. 00 1.5 0 8. 00 2. 77 4. 00 1.5 0 2. 00 0. 75 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 2. 00 1.1 3 4. 00 2. 36 2. 00 1.2 5 4. 00 2. 38 2. 00 1.2 5 2. 00 1.2 5 Po go ste m on pa tch ou li (p at ch ou li) 1.0 0 3. 00 1.6 9 4. 00 2. 36 2. 00 1.2 5 4. 00 2. 38 2. 00 1.2 5 2. 00 1.2 5 Sa nt al um al bu m (s an da lw oo d) 0. 50 0. 50 0. 53 1.0 0 1.0 9 0. 50 0. 56 1.0 0 1.1 0 0. 75 0. 84 0. 50 0. 56 St yr ax be nz oi n (b en zo in ) 2. 00 2. 00 0. 63 2. 00 0. 68 2. 00 0. 75 4. 00 1.3 8 2. 00 0. 75 2. 00 0. 75 Sy zy giu m ar om at icu m (c lo ve ) 1.0 0 2. 00 1.1 3 2. 00 1.1 8 2. 00 1.2 5 2. 00 1.1 9 2. 00 1.2 5 1.5 0 0. 94 � ym us vu lga ris (th ym e) 2. 00 2. 00 0. 63 4. 00 1.3 6 2. 00 0. 75 4. 00 1.3 8 2. 00 0. 75 2. 00 0. 75 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 50 1.0 0 1.0 6 2. 00 2. 18 0. 50 0. 56 1.0 0 1.1 0 1.0 0 1.1 3 0. 75 0. 84 Evidence-Based Complementary and Alternative Medicine 13 Ta bl e 3: C on tin ue d. G M RS A AT C C 33 59 2 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 4. 00 4. 00 1.0 0 4. 00 0. 79 3. 00 0. 75 4. 00 1.0 0 2. 00 0. 75 2. 50 0. 63 Ci nn am om um ze yl an icu m (c in na m on ) 0. 13 1.0 0 3. 97 1.0 0 3. 92 1.0 0 3. 97 1.0 0 3. 97 0. 75 3. 07 1.0 0 3. 97 Ci tru sb er ga m ia (b er ga m ot ) 6. 00 4. 00 0. 83 2. 00 0. 31 4. 00 0. 83 3. 00 0. 63 4. 00 1.3 3 4. 00 0. 83 Ci tru sr et icu la ta (m an da rin ) 2. 40 2. 00 0. 67 6. 00 1.6 8 4. 00 1.3 3 4. 00 1.3 3 6. 00 2. 75 3. 00 1.0 0 Co m m ip ho ra m yr rh a (m yr rh ) 0. 25 0. 50 1.0 6 0. 25 0. 52 0. 25 0. 53 0. 25 0. 53 0. 75 1.6 9 0. 25 0. 53 Cy m bo po go n cit ra tu s (le m on gr as s) 0. 75 2. 00 1.5 8 1.0 0 0. 74 1.0 0 0. 79 1.0 0 0. 79 1.5 0 1.3 8 2. 00 1.5 8 Cy m bo po go n m ar tin ii (p al m ar os a) 1.0 0 2. 00 1.2 5 2. 00 1.1 4 3. 00 1.8 8 2. 00 1.2 5 2. 00 1.5 0 2. 00 1.2 5 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 2. 00 2. 00 0. 75 3. 00 0. 96 3. 00 1.1 3 2. 00 0. 75 3. 00 1.5 0 4. 00 1.5 0 H eli ch ry su m ita lic um (im m or te lle ) 1.5 0 3. 00 1.3 8 2. 00 0. 81 2. 00 0. 92 2. 00 0. 92 3. 00 1.7 5 2. 00 0. 92 Ku nz ea er ico id es (k an uk a) 4. 00 4. 00 1.0 0 2. 00 0. 39 3. 00 0. 75 2. 50 0. 63 4. 00 1.5 0 3. 00 0. 75 La ur us no bi lis (b ay ) 1.0 0 1.5 0 0. 94 1.5 0 0. 86 1.0 0 0. 63 1.0 0 0. 63 1.5 0 1.1 3 1.0 0 0. 63 La va nd ul a an gu sti fo lia (la ve nd er ) 2. 00 4. 00 1.5 0 2. 00 0. 64 2. 00 0. 75 2. 00 0. 75 4. 00 2. 00 4. 00 1.5 0 Le pt os pe rm um sc op ar iu m (m an uk a) 1.0 0 2. 00 1.2 5 2. 00 1.1 4 1.0 0 0. 63 2. 00 1.2 5 1.0 0 0. 75 1.0 0 0. 63 Li tse a cu be ba (m ay ch an g) 0. 50 1.5 0 1.6 9 1.0 0 1.0 7 1.0 0 1.1 3 1.0 0 1.1 3 1.0 0 1.2 5 1.0 0 1.1 3 M ela leu ca al te rn ifo lia (te at re e) 2. 00 2. 00 0. 75 4. 00 1.2 9 2. 00 0. 75 4. 00 1.5 0 3. 00 1.5 0 2. 00 0. 75 M ela leu ca vi rid ifl or a (n ia ou li) 2. 00 4. 00 1.5 0 4. 00 1.2 9 4. 00 1.5 0 4. 00 1.5 0 3. 00 1.5 0 3. 00 1.1 3 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 3 . 00 1.8 8 2. 00 1.1 4 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.5 0 2. 00 1.2 5 Po go ste m on pa tch ou li (p at ch ou li) 0. 25 1.7 5 3. 72 1.0 0 2. 07 1.8 0 3. 83 1.8 0 3. 83 1.5 0 3. 38 1.8 0 3. 83 Sa nt al um al bu m (s an da lw oo d) 0. 25 0. 50 1.0 6 0. 50 1.0 4 0. 25 0. 53 0. 25 0. 53 0. 38 0. 84 0. 25 0. 53 St yr ax be nz oi n (b en zo in ) 2. 00 2. 00 0. 75 2. 00 0. 64 2. 00 0. 75 2. 00 0. 75 2. 00 1.0 0 2. 00 0. 75 Sy zy giu m ar om at icu m (c lo ve ) 1.0 0 1.5 0 0. 94 1.0 0 0. 57 1.0 0 0. 63 1.0 0 0. 63 1.5 0 1.1 3 1.0 0 0. 63 � ym us vu lga ris (th ym e) 1.0 0 4. 00 2. 50 4. 00 2. 29 2. 00 1.2 5 4. 00 2. 50 4. 00 3. 00 2. 00 1.2 5 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 13 0. 50 1.9 9 0. 75 2. 94 0. 50 1.9 9 0. 25 0. 99 0. 50 2. 05 0. 38 1.4 9 14 Evidence-Based Complementary and Alternative Medicine Ta bl e 3: C on tin ue d. S. ep id er m id is AT C C 22 23 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 2. 00 2. 00 0. 56 2. 00 0. 56 2. 00 0. 56 1.5 0 0. 42 8. 00 2. 67 6. 00 1.6 9 Ci nn am om um ze yl an icu m (c in na m on ) 1.0 0 2. 00 1.0 6 1.5 0 0. 80 2. 00 1.0 6 2. 00 1.0 6 2. 00 1.1 7 2. 00 1.0 6 Ci tru sb er ga m ia (b er ga m ot ) 3. 00 3. 00 0. 59 2. 00 0. 40 3. 00 0. 59 4. 00 0. 79 4. 00 1.0 0 4. 00 0. 79 Ci tru sr et icu la ta (m an da rin ) 4. 00 8. 00 1.2 5 4. 00 0. 63 4. 00 0. 63 3. 50 0. 55 8. 00 1.6 7 12 .0 0 1.8 8 Co m m ip ho ra m yr rh a (m yr rh ) 0. 50 1.0 0 1.0 3 3. 00 3. 09 1.0 0 1.0 3 2. 00 2. 06 0. 75 0. 81 1.0 0 1.0 3 Cy m bo po go n cit ra tu s (le m on gr as s) 1.0 0 1.0 0 0. 53 1.0 0 0. 53 1.0 0 0. 53 2. 00 1.0 6 1.0 0 0. 58 1.0 0 0. 53 Cy m bo po go n m ar tin ii (p al m ar os a) 1.0 0 1.0 0 0. 53 2. 00 1.0 6 1.5 0 0. 80 1.5 0 0. 80 2. 00 1.1 7 2. 00 1.0 6 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 2. 00 6. 00 1.6 9 6. 00 1.6 9 3. 00 0. 84 6. 00 1.6 9 4. 00 1.3 3 6. 00 1.6 9 H eli ch ry su m ita lic um (im m or te lle ) 2. 00 2. 00 0. 56 3. 00 0. 84 2. 00 0. 56 3. 00 0. 84 2. 75 0. 92 2. 00 0. 56 Ku nz ea er ico id es (k an uk a) 2. 00 6. 00 1.6 9 4. 00 1.1 3 4. 00 1.1 3 4. 00 1.1 3 6. 00 2. 00 2. 00 0. 56 La ur us no bi lis (b ay ) 1.0 0 2. 00 1.0 6 2. 00 1.0 6 1.0 0 0. 53 2. 00 1.0 6 2. 00 1.1 7 2. 00 1.0 6 La va nd ul a an gu sti fo lia (la ve nd er ) 2. 00 2. 00 0. 56 2. 00 0. 56 4. 00 1.1 3 2. 00 0. 56 2. 00 0. 67 2. 00 0. 56 Le pt os pe rm um sc op ar iu m (m an uk a) 1.0 0 1.0 0 0. 53 1.0 0 0. 53 1.0 0 0. 53 1.0 0 0. 53 1.0 0 0. 58 1.0 0 0. 53 Li tse a cu be ba (m ay ch an g) 0. 75 1.5 0 1.0 5 1.0 0 0. 70 1.0 0 0. 70 1.0 0 0. 70 1.0 0 0. 75 1.5 0 1.0 5 M ela leu ca al te rn ifo lia (te at re e) 4. 00 3. 50 0. 55 3. 50 0. 55 8. 00 1.2 5 3. 50 0. 55 3. 00 0. 63 3. 50 0. 55 M ela leu ca vi rid ifl or a (n ia ou li) 2. 00 2. 00 0. 56 4. 00 1.1 3 2. 00 0. 56 2. 00 0. 56 4. 00 1.3 3 4. 00 1.1 3 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 2. 00 1.0 6 2. 00 1.0 6 3. 00 1.5 9 2. 00 1.0 6 2. 00 1.1 7 2. 00 1.0 6 Po go ste m on pa tch ou li (p at ch ou li) 0. 25 1.7 5 3. 55 1.5 0 3. 05 1.7 5 3. 55 1.5 0 3. 05 1.7 5 3. 65 1.5 0 3. 05 Sa nt al um al bu m (s an da lw oo d) 0. 13 0. 25 0. 97 0. 63 2. 42 0. 50 1.9 4 0. 3 8 1.4 5 0. 50 1.9 6 0. 38 1.4 5 St yr ax be nz oi n (b en zo in ) 3. 00 3. 00 0. 59 3. 00 0. 59 4. 00 0. 79 3. 00 0. 59 6. 00 1.5 0 4. 00 0. 79 Sy zy giu m ar om at icu m (c lo ve ) 1.0 0 2. 00 1.0 6 2. 00 1.0 6 2. 00 1.0 6 2. 00 1.0 6 2. 00 1.1 7 1.5 0 0. 80 � ym us vu lga ris (th ym e) 0. 75 2. 00 1.4 0 1.5 0 1.0 5 3. 00 2. 09 1.0 0 0. 70 2. 00 1.5 0 2. 00 1.4 0 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 13 1.0 0 3. 88 0. 75 2. 91 0. 50 1.9 4 0. 75 2. 91 0. 50 1.9 6 0. 50 1.9 4 Evidence-Based Complementary and Alternative Medicine 15 Ta bl e 3: C on tin ue d. P. ac ne sA TC C 11 82 7 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds i ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 2. 00 2. 00 0. 56 8. 00 3. 33 2. 00 0. 90 2. 00 0. 63 2. 00 0. 63 6. 00 3. 50 Ci nn am om um ze yl an icu m (c in na m on ) 1.0 0 2. 00 1.0 6 1.0 0 0. 67 2. 00 1.4 0 1.5 0 0. 84 1.0 0 0. 56 1.5 0 1.2 5 Ci tru sb er ga m ia (b er ga m ot ) 2. 00 2. 00 0. 56 6. 50 2. 71 8. 00 3. 60 8. 00 2. 50 2. 00 0. 63 3. 00 1.7 5 Ci tru sr et icu la ta (m an da rin ) 0. 50 3. 50 3. 61 3. 00 3. 50 2. 00 2. 40 3. 00 3. 19 2. 00 2. 13 2. 00 2. 67 Co m m ip ho ra m yr rh a (m yr rh ) 0. 50 0. 50 0. 52 2. 00 2. 33 0. 50 0. 60 2. 00 2. 13 1.0 0 1.0 6 1.0 0 1.3 3 Cy m bo po go n cit ra tu s (le m on gr as s) 0. 50 1.0 0 1.0 3 1.0 0 1.1 7 2. 00 2. 40 1.0 0 1.0 6 1.0 0 1.0 6 1.0 0 1.3 3 Cy m bo po go n m ar tin ii (p al m ar os a) 1.0 0 1.5 0 0. 80 1.5 0 1.0 0 1.0 0 0. 70 2. 00 1.1 3 1.0 0 0. 56 1.0 0 0. 83 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 2. 00 4. 00 1.1 3 6. 00 2. 50 2. 00 0. 90 8. 00 2. 50 6. 00 1.8 8 5. 00 2. 92 H eli ch ry su m ita lic um (im m or te lle ) 1.0 0 2. 00 1.0 6 5. 00 3. 33 4. 00 2. 80 0. 75 0. 42 2. 00 1.1 3 2. 00 1.6 7 Ku nz ea er ico id es (k an uk a) 2. 00 2. 00 0. 56 2. 00 0. 83 6. 00 2. 70 4. 00 1.2 5 3. 00 0. 94 3. 00 1.7 5 La ur us no bi lis (b ay ) 1.0 0 2. 00 1.0 6 2. 00 1.3 3 3. 00 2. 10 2. 00 1.1 3 1.5 0 0. 84 1.5 0 1.2 5 La va nd ul a an gu sti fo lia (la ve nd er ) 2. 00 2. 00 0. 56 2. 00 0. 83 2. 00 0. 90 4. 00 1.2 5 1.5 0 0. 47 2. 00 1.1 7 Le pt os pe rm um sc op ar iu m (m an uk a) 0. 55 1.0 0 0. 94 1.0 0 1.0 8 2. 00 2. 22 2. 00 1.9 4 2. 00 1.9 4 2. 00 2. 48 Li tse a cu be ba (m ay ch an g) 0. 88 1.5 0 0. 90 1.0 0 0. 73 2. 00 1.5 4 1.0 0 0. 63 1.0 0 0. 63 1.5 0 1.3 5 M ela leu ca al te rn ifo lia (te at re e) 2. 00 4. 00 1.1 3 2. 00 0. 83 3. 00 1.3 5 2. 00 0. 63 6. 00 1.8 8 6. 00 3. 50 M ela leu ca vi rid ifl or a (n ia ou li) 1.0 0 2. 00 1.0 6 2. 00 1.3 3 2. 00 1.4 0 5. 00 2. 81 2. 00 1.1 3 2. 00 1.6 7 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 2. 00 1.0 6 2. 00 1.3 3 2. 00 1.4 0 2. 00 1.1 3 2. 00 1.1 3 2. 00 1.6 7 Po go ste m on pa tch ou li (p at ch ou li) 0. 50 1.0 0 1.0 3 2. 00 2. 33 1.5 0 1.8 0 2. 00 2. 13 1.0 0 1.0 6 2. 50 3. 33 Sa nt al um al bu m (s an da lw oo d) 0. 6 9 2. 00 1.5 1 2. 00 1.7 8 2. 00 1.8 5 0. 60 0. 47 1.5 0 1.1 8 2. 00 2. 12 St yr ax be nz oi n (b en zo in ) 1.0 0 2. 00 1.0 6 4. 00 2. 67 3. 00 2. 10 3. 00 1.6 9 7.0 0 3. 94 2. 00 1.6 7 Sy zy giu m ar om at icu m (c lo ve ) 0. 50 1.0 0 1.0 3 1.5 0 1.7 5 2. 00 2. 40 2. 00 2. 13 1.0 0 1.0 6 2. 00 2. 67 � ym us vu lga ris (th ym e) 1.0 0 1.5 0 0. 80 2. 00 1.3 3 2. 00 1.4 0 2. 00 1.1 3 1.5 0 0. 84 2. 00 1.6 7 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 50 1.0 0 1.0 3 1.0 0 1.1 7 2. 00 2. 40 1.0 0 1.0 6 1.5 0 1.5 9 1.0 0 1.3 3 16 Evidence-Based Complementary and Alternative Medicine Ta bl e 3: C on tin ue d. E. co li AT C C 87 39 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 2. 00 2. 63 0. 82 4. 00 1.5 0 3. 00 1.1 3 3. 00 1.1 3 2. 00 0. 75 2. 63 0. 98 Ci nn am om um ze yl an icu m (c in na m on ) 2. 00 2. 00 0. 63 2. 00 0. 75 2. 00 0. 75 2. 00 0. 75 2. 00 0. 75 3. 00 1.1 3 Ci tru sb er ga m ia (b er ga m ot ) 3. 50 4. 00 0. 82 4. 00 1.0 7 1.8 5 0. 50 4. 00 1.0 7 4. 00 1.0 7 4. 00 1.0 7 Ci tru sr et icu la ta (m an da rin ) 2. 40 4. 00 1.0 8 4. 00 1.3 3 8. 00 2. 67 1.5 0 0. 50 4. 00 1.3 3 2. 00 0. 67 Co m m ip ho ra m yr rh a (m yr rh ) 2. 00 1.7 0 0. 53 2. 00 0. 75 1.4 0 0. 53 3. 00 1.1 3 1.4 0 0. 53 1.4 0 0. 53 Cy m bo po go n cit ra tu s (le m on gr as s) 1.0 0 1.5 0 0. 84 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 Cy m bo po go n m ar tin ii (p al m ar os a) 1.0 0 2. 00 1.1 3 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 2. 00 4. 00 1.2 5 4. 00 1.5 0 4. 00 1.5 0 4. 00 1.5 0 4. 00 1.5 0 4. 00 1.5 0 H eli ch ry su m ita lic um (im m or te lle ) 2. 00 2. 00 0. 63 3. 00 1.1 3 2. 00 0. 75 3. 00 1.1 3 2. 00 0. 75 2. 00 0. 75 Ku nz ea er ico id es (k an uk a) 2. 00 4. 00 1.2 5 2. 00 0. 75 3. 00 1.1 3 2. 00 0. 75 3. 00 1.1 3 2. 00 0. 75 La ur us no bi lis (b ay ) 1.0 0 3. 00 1.6 9 2. 00 1.2 5 4. 00 2. 50 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 La va nd ul a an gu sti fo lia (la ve nd er ) 2. 00 4. 00 1.2 5 2. 00 0. 75 3. 00 1.1 3 2. 00 0. 75 4. 00 1.5 0 2. 00 0. 75 Le pt os pe rm um sc op ar iu m (m an uk a) 1.7 5 2. 00 0. 70 3. 00 1.2 3 4. 00 1.6 4 2. 00 0. 82 2. 00 0. 82 2. 00 0. 82 Li tse a cu be ba (m ay ch an g) 1.0 0 3. 00 1.6 9 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 M ela leu ca al te rn ifo lia (te at re e) 2. 00 4. 00 1.2 5 2. 00 0. 75 4. 00 1.5 0 2. 00 0. 75 4. 00 1.5 0 4. 00 1.5 0 M ela leu ca vi rid ifl or a (n ia ou li) 2. 00 4. 00 1.2 5 2. 00 0. 75 2. 00 0. 75 2. 00 0. 75 4. 00 1.5 0 4. 00 1.5 0 M eli ssa offi cin al is (le m on ba lm ) 2. 00 4. 00 1.2 5 2. 00 0. 75 6. 00 2. 25 2. 00 0. 75 4. 00 1.5 0 2. 00 0. 75 Po go ste m on pa tch ou li (p at ch ou li) 0. 88 1.5 0 0. 95 2. 00 1.3 9 2. 00 1.3 9 2. 00 1.3 9 2. 00 1.3 9 2. 00 1.3 9 Sa nt al um al bu m (s an da lw oo d) 0. 50 2. 00 2. 13 1.0 0 1.1 3 2. 00 2. 25 2. 00 2. 25 1.0 0 1.1 3 2. 00 2. 25 St yr ax be nz oi n (b en zo in ) 2. 00 2. 00 0. 63 2. 00 0. 75 5. 00 1.8 8 2. 00 0. 75 2. 00 0. 75 4. 00 1.5 0 Sy zy giu m ar om at icu m (c lo ve ) 1.0 0 2. 00 1.1 3 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 2. 00 1.2 5 � ym us vu lga ris (th ym e) 2. 00 4. 00 1.2 5 2. 00 0. 75 2. 00 0. 75 2. 00 0. 75 4. 00 1.5 0 2. 00 0. 75 Ve tiv er ia zi za ni oi de s( ve tiv er ) 0. 60 2. 00 1.7 9 2. 00 1.9 2 3. 00 2. 88 2. 00 1.9 2 3. 00 2. 88 1.0 0 0. 96 Evidence-Based Complementary and Alternative Medicine 17 Ta bl e 3: C on tin ue d. P. ae ru gi no sa AT C C 27 85 8 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 1.0 0 0. 83 0. 50 0. 39 1.0 0 1.0 0 2. 00 2. 00 Ci nn am om um ze yl an icu m (c in na m on ) 0. 75 2. 00 2. 33 1.0 0 1.0 0 1.0 0 1.0 0 0. 75 0. 71 1.0 0 1.1 7 1.5 0 1.7 5 Ci tru sb er ga m ia (b er ga m ot ) 1.5 0 1.0 0 0. 83 1.0 0 0. 67 1.0 0 0. 67 2. 00 1.2 4 1.5 0 1.2 5 1.0 0 0. 83 Ci tru sr et icu la ta (m an da rin ) 1.5 0 2. 00 1.6 7 2. 00 1.3 3 1.0 0 0. 67 2. 00 1.2 4 1.5 0 1.2 5 1.0 0 0. 83 Co m m ip ho ra m yr rh a (m yr rh ) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 3. 00 2. 50 2. 00 1.5 7 1.0 0 1.0 0 1.0 0 1.0 0 Cy m bo po go n cit ra tu s (le m on gr as s) 1.0 0 1.5 0 1.5 0 1.0 0 0. 83 1.5 0 1.2 5 1.0 0 0. 79 1.0 0 1.0 0 1.0 0 1.0 0 Cy m bo po go n m ar tin ii (p al m ar os a) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 1.0 0 0. 83 1.0 0 0. 79 0. 58 0. 58 1.5 0 1.5 0 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 2. 00 2. 00 1.5 0 2. 00 1.1 7 1.0 0 0. 58 3. 00 1.6 1 2. 00 1.5 0 1.0 0 0. 75 H eli ch ry su m ita lic um (im m or te lle ) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 1.5 0 1.2 5 1.0 0 0. 79 2. 00 2. 00 1.0 0 1.0 0 Ku nz ea er ico id es (k an uk a) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 2. 00 1.6 7 1.0 0 0. 79 3. 00 3. 00 1.0 0 1.0 0 La ur us no bi lis (b ay ) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 2. 00 1.6 7 1.0 0 0. 79 1.0 0 1.0 0 1.0 0 1.0 0 La va nd ul a an gu sti fo lia (la ve nd er ) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 3. 00 2. 50 1.0 0 0. 79 1.5 0 1.5 0 1.0 0 1.0 0 Le pt os pe rm um sc op ar iu m (m an uk a) 2. 00 1.0 0 0. 75 1.0 0 0. 58 1.0 0 0. 58 1.0 0 0. 54 1.0 0 0. 75 1.0 0 0. 75 Li tse a cu be ba (m ay ch an g) 1.5 0 3. 00 2. 50 1.0 0 0. 67 1.0 0 0. 67 1.0 0 0. 62 1.0 0 0. 83 1.5 0 1.2 5 M ela leu ca al te rn ifo lia (te at re e) 2. 00 1.0 0 0. 75 1.0 0 0. 58 1.0 0 0. 58 1.0 0 0. 54 1.0 0 0. 75 1.5 0 1.1 3 M ela leu ca vi rid ifl or a (n ia ou li) 1.5 0 1.0 0 0. 83 1.0 0 0. 67 1.5 0 1.0 0 1.0 0 0. 62 1.5 0 1.2 5 1.0 0 0. 83 M eli ssa offi cin al is (le m on ba lm ) 2. 00 1.0 0 0. 75 1.0 0 0. 58 1.5 0 0. 88 1.0 0 0. 54 2. 50 1.8 8 1.0 0 0. 75 Po go ste m on pa tch ou li (p at ch ou li) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 2. 00 1.6 7 2. 00 1.5 7 1.0 0 1.0 0 0. 75 0. 75 Sa nt al um al bu m (s an da lw oo d) 1.5 0 1.0 0 0. 83 1.0 0 0. 67 1.5 0 1.0 0 1.0 0 0. 62 1.0 0 0. 83 1.0 0 0. 83 St yr ax be nz oi n (b en zo in ) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 1.0 0 0. 83 1.0 0 0. 79 2. 00 2. 00 1.5 0 1.5 0 Sy zy giu m ar om at icu m (c lo ve ) 1.0 0 1.0 0 1.0 0 1.0 0 0. 83 1.0 0 0. 83 0. 50 0. 39 2. 00 2. 00 1.0 0 1.0 0 � ym us vu lga ris (th ym e) 1.0 0 2. 00 2. 00 1.0 0 0. 83 1.5 0 1.2 5 2. 00 1.5 7 1.0 0 1.0 0 1.0 0 1.0 0 Ve tiv er ia zi za ni oi de s( ve tiv er ) 1.0 0 2. 00 2. 00 1.0 0 0. 83 2. 00 1.6 7 1.0 0 0. 79 1.0 0 1.0 0 1.5 0 1.5 0 18 Evidence-Based Complementary and Alternative Medicine Ta bl e 3: C on tin ue d. C. al bi ca ns AT C C 10 23 1 Al oe ve ra Ca len du la offi cin al is H yp er icu m pe rfo ra tu m Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis Es se nt ia lo il EO M IC M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C M IC Σ FI C Ca na ng a od or at a (y la ng yl an g) 1.0 0 1.5 0 0. 84 1.0 0 0. 53 1.5 0 0. 94 1.0 0 0. 53 1.0 0 0. 56 1.5 0 0. 88 Ci nn am om um ze yl an icu m (c in na m on ) 0. 50 0. 50 0. 53 0. 50 0. 52 0. 75 0. 84 0. 50 0. 52 0. 75 0. 80 0. 75 0. 81 Ci tru sb er ga m ia (b er ga m ot ) 1.0 0 1.0 0 0. 56 1.0 0 0. 53 2. 00 1.2 5 1.0 0 0. 53 3. 00 1.6 9 1.0 0 0. 58 Ci tru sr et icu la ta (m an da rin ) 2. 00 1.7 5 0. 55 3. 00 0. 84 1.0 0 0. 51 6. 00 1.6 9 2. 00 0. 63 1.5 5 0. 52 Co m m ip ho ra m yr rh a (m yr rh ) 1.0 0 1.0 0 0. 56 1.0 0 0. 53 2. 00 1.2 5 1.0 0 0. 53 1.5 0 0. 84 1.5 0 0. 88 Cy m bo po go n cit ra tu s (le m on gr as s) 0. 63 0. 75 0. 64 0. 63 0. 52 1.0 0 0. 92 0. 63 0. 52 1.0 0 0. 86 0. 75 0. 66 Cy m bo po go n m ar tin ii (p al m ar os a) 0. 75 1.5 0 1.0 9 1.0 0 0. 70 1.0 0 0. 79 1.0 0 0. 70 1.0 0 0. 73 1.0 0 0. 75 Eu ca ly pt us glo bu lu s( eu ca ly pt us ) 1.0 0 1.5 0 0. 84 4. 00 2. 13 1.0 0 0. 63 1.5 0 0. 80 6. 00 3. 38 1.0 0 0. 58 H eli ch ry su m ita lic um (im m or te lle ) 2. 00 1.7 5 0. 55 2. 00 0. 56 1.0 0 0. 51 1.8 0 0. 51 2. 00 0. 63 1.5 5 0. 52 Ku nz ea er ico id es (k an uk a) 1.5 0 0. 75 0. 30 1.5 0 0. 55 1.0 0 0. 46 1.4 0 0. 51 3. 00 1.1 9 1.0 0 0. 42 La ur us no bi lis (b ay ) 1.0 0 1.2 5 0. 70 1.0 0 0. 5 3 1 .5 0 0. 94 1.5 0 0. 80 1.0 0 0. 56 1.0 0 0. 58 La va nd ul a an gu sti fo lia (la ve nd er ) 1.0 0 0. 80 0. 45 1.0 0 0. 53 1.5 0 0. 94 1.0 0 0. 53 1.5 0 0. 84 1.5 0 0. 88 Le pt os pe rm um sc op ar iu m (m an uk a) 1.0 0 1.0 0 0. 56 1.0 0 0. 53 1.0 0 0. 63 1.0 0 0. 53 1.0 0 0. 56 0. 95 0. 55 Li tse a cu be ba (m ay ch an g) 0. 50 1.0 0 1.0 6 0. 50 0. 52 1.0 0 1.1 3 0. 50 0. 52 1.0 0 1.0 6 1.0 0 1.0 8 M ela leu ca al te rn ifo lia (te at re e) 1.5 0 0. 83 0. 33 1.5 0 0. 55 1.5 0 0. 69 1.5 0 0. 55 1.5 0 0. 59 1.5 0 0. 63 M ela leu ca vi rid ifl or a (n ia ou li) 1.0 0 2. 00 1.1 3 1.0 0 0. 53 1.0 0 0. 63 1.0 0 0. 53 0. 75 0. 42 2. 00 1.1 7 M eli ssa offi cin al is (le m on ba lm ) 1.0 0 1.5 0 0. 84 1.0 0 0. 53 1.0 0 0. 63 1.0 0 0. 53 1.5 0 0. 84 1.0 0 0. 58 Po go ste m on pa tch ou li (p at ch ou li) 1.0 0 1.2 5 0. 70 6. 00 3. 19 1.0 0 0. 63 2. 00 1.0 6 1.0 0 0. 56 1.2 5 0. 73 Sa nt al um al bu m (s an da lw oo d) 1.0 0 0. 50 0. 28 1.0 0 0. 53 1.0 0 0. 63 1.0 0 0. 53 1.0 0 0. 56 1.0 0 0. 58 St yr ax be nz oi n (b en zo in ) 2. 00 1.0 0 0. 31 2. 00 0. 56 8. 00 3. 00 1.0 0 0. 28 1.0 0 0. 31 1.0 0 0. 33 Sy zy giu m ar om at icu m (c lo ve ) 0. 50 1.0 0 1.0 6 0. 75 0. 77 1.0 0 1.1 3 0. 75 0. 77 1.0 0 1.0 6 1.0 0 1.0 8 � ym us vu lga ris (th ym e) 1.0 0 4. 37 5 2. 46 1.0 0 0. 53 2. 00 1.2 5 1.0 0 0. 53 1.5 0 0. 84 1.0 0 0. 58 Ve tiv er ia zi za ni oi de s( ve tiv er ) 1.0 0 1.0 0 0. 56 1.0 0 0. 53 1.0 0 0. 63 1.0 0 0. 53 1.0 0 0. 56 1.5 0 0. 88 ∗ N ot ew or th y an tim ic ro bi al ac tiv ity hi gh lig ht ed in bo ld . † Sy ne rg ist ic in te ra ct io ns hi gh lig ht ed in bo ld ita lic s. Evidence-Based Complementary and Alternative Medicine 19 0 20 40 60 80 100 120 140 160 Aloe vera Calendula officinalis Hypericum perforatum Persea americana Prunus armeniaca Simmondsia chinensis Number of interactions Ca rr ie r o il Antagonism Indifference Additive Synergy Figure 2: Summary of interactive profiles of essential oil with carrier oil combinations. the antimicrobial activity of the essential oils, when diluted with the carrier oils, did not result in antagonism. The carrier oils that most frequently exhibited promising synergy were P. americana (ten combinations), followed by A. vera (nine combinations). While dilution of the essential oils with carrier oils in most cases resulted in a slight decrease in antimicrobial activity, it was interesting to note that the antimicrobial activity of several combinations was actually enhanced when tested against selected pathogens. This was observed for combinations with A. vera and S. chinensis, which increased antimicrobial activity against B. epidermidis, B. linens, and P. aeruginosa. It raises the question as to whether the permeating properties exhibited by S. chinensis carrier oil and A. vera gel (carrier oil research is lacking) are able to enhance permeation into the bacterial cell wall [17, 18], an area of investigation which should be encouraged. The carrier oil H. perforatum increased the antimicrobial activity of several essential oils against B. epidermidis. Calendula officinalis and P. americana increased the essential oil activity against P. aeruginosa. What is remarkable, though, is that no antimicrobial antagonism was observed between any of the 1518 carrier oils: essential oil combinations investigated, validating the aroma-therapeutic use of combining carrier oils with essential oils. 3.3. Cytotoxicity Studies. The percentage cytotoxicity of each carrier oil is shown in Table 2. None of the carrier oils were found to be toxic. In fact, A. vera, C. officinalis and P. americana were found to show no trace of cytotoxicity after 24 hrs when tested in the brine shrimp lethality assay. The low cytotoxicity shown by S. chinensis and C. officinalis has also previously been observed [17, 19]. The cytotoxicity of H. perforatum, P. americana, and P. armeniaca carrier oils, however, is reported for the first time in this study. The cytotoxicity profiles of the controls and the essen- tial oils alone and in combination with the carrier oils are displayed in Table 4. The majority of the essential oils were found to be cytotoxic at 24 and 48 hrs, even at a low concentration of 1.00 mg/mL. The essential oils that were found to be nontoxic after 48 hrs were Helichrysum italicum (immortelle), Laurus nobilis (bay), and Vetiveria zizanioides (vetiver). A previous report on the cytotoxicity of L. nobilis is limited to its potency against Camptomyia corticalis [20]. Helichrysum italicum and V. zizanioides were also investigated previously [20], with no reported cytotoxic- ity. Aloe vera and S. chinensis reduced the cytotoxicity of 14 essential oils after 24 hrs, followed by H. perforatum, P. americana, and P. armeniaca that decreased the cytotoxicity of 13 essential oils, and lastly C. officinalis decreased the cytotoxicity of 11 oils. Considering that essential oils may be applied daily to the skin, this highlights A. vera and S. chinensis as the carrier oils that would be most beneficial for topical use. Due to three of the carrier oils displaying no cytotoxicity at 24 hrs, the ΣFIC could not be calculated (FIC calculation requires an endpoint value); however, values could be calculated for 48 hr exposure. After 48 hrs, 18 out of 23 combinations of essential oils with Aloe vera resulted in a synergistic decrease in cytotoxicity. Seventeen synergistic interactions were observed withH. perforatum and 14 with C. officinalis. There is a statistical significant difference between the two periods (all p < 0.05). Aloe vera was the carrier oil that showed the most pronounced quenching of essential oil cytotoxicity at both 24 and 48 hrs. It draws attention to whether the vitamin E in the carrier oil may contribute towards this effect. Previous studies have shown vitamin E to decrease the cytotoxicity of medicines [22], and vitamin E derivative �훼-tocopherol has also been shown to decrease toxicity [23]. 20 Evidence-Based Complementary and Alternative Medicine Ta bl e 4: Es se nt ia lo il cy to to xi ci ty al on ea nd in co m bi na tio n w ith ca rr ie ro ils (% m or ta lit y) . Es se nt ia lo il Cy to to xi ci ty al on e Al oe ve ra Ca le nd ul a offi ci na lis H yp er icu m pe rf or at um Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis 24 hr s 48 hr s 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C Ca na ng a od or at a (y la ng yl an g) 77 .3 6∗ 94 .15 4. 60 10 .2 0 0 .2 4 † 6. 95 12 .4 4 0. 29 5. 54 13 .5 9 0. 24 0. 67 8. 96 0. 22 0. 94 17. 03 0. 91 1.7 4 11. 16 0. 29 Ci nn am om um ze yl an icu m (c in na m on ) 97 .6 8 97 .6 8 2. 58 5. 56 0. 13 76 .9 5 87 .9 2 2. 00 25 .7 1 64 .9 4 1.1 6 0. 00 40 .6 7 1.0 0 10 0. 00 10 0. 00 5. 33 ‡ 10 .6 7 40 .8 6 1.0 6 Ci tru sb er ga m ia (b er ga m ot ) 94 .2 9 96 .9 5 78 .5 8 89 .4 8 2. 11 66 .3 6 84 .6 8 1.9 3 79 .16 91 .4 8 1.6 3 0. 49 19 .7 3 0. 48 3. 75 19 .2 7 1.0 3 4. 63 23 .17 0. 60 Ci tru sr et icu la ta (m an da rin ) 73 .6 2 90 .9 6 6. 76 13 .0 3 0. 31 41 .5 4 64 .3 5 1.4 9 9.9 3 20 .2 6 0. 37 0. 57 13 .12 0. 33 0. 63 19 .3 0 1.0 4 11. 94 10 0. 00 2. 62 Co m m ip ho ra m yr rh a (m yr rh ) 76 .9 9 92 .9 9 3. 86 9.6 6 0. 23 9.3 3 18 .0 5 0. 42 4. 06 8. 06 0. 15 12 .6 1 83 .33 2. 07 1.4 1 35 .8 3 1.9 2 3. 32 29 .2 1 0. 76 Cy m bo po go n cit ra tu s (le m on gr as s) 10 0. 00 10 0. 00 9.4 9 21 .4 2 0. 50 71 .4 3 82 .3 8 1.8 6 19 .52 44 .0 1 0. 78 40 .4 3 54 .9 0 1.3 4 1.1 0 27 .5 4 1.4 6 6. 27 90 .6 1 2. 33 Cy m bo po go n m ar tin ii (p al m ar os a) 93 .32 94 .4 1 3. 64 15 .4 0 0. 37 2. 95 13 .6 5 0. 31 10 .37 30 .12 0. 54 0. 00 18 .19 0. 45 1.5 4 28 .9 3 1.5 5 10 0. 00 10 0. 00 2. 60 Eu ca ly pt us glo bu lu s (e uc al yp tu s) 15 .4 8 77 .6 6 0. 00 4. 00 0. 10 0. 98 8. 31 0. 20 2. 57 7.2 7 0. 14 0. 72 30 .8 6 0. 80 1.3 2 5. 19 0. 28 2. 06 9.4 5 0. 26 H eli ch ry su m ita lic um (im m or te lle ) 20 .4 1 40 .0 9 2. 88 10 .5 5 0. 33 0. 47 23 .8 1 0. 72 2. 89 7.7 5 0. 20 5. 98 39 .8 6 1.2 7 1.9 3 14 .0 1 0. 85 7.7 8 90 .0 0 2. 99 Ku nz ea er ico id es (k an uk a) 28 .0 8 82 .9 4 4. 00 16 .16 0. 40 3. 36 6. 06 0. 14 0. 52 2. 64 0. 05 3. 84 5. 16 0. 13 0. 94 13 .37 0. 72 3. 28 72 .39 1.9 4 La ur us no bi lis (b ay ) 31 .8 9 42 .9 2 0. 53 8. 84 0. 27 4. 35 9.1 8 0. 27 7.2 3 9.7 8 0. 24 2. 34 7.8 6 0. 24 9.8 9 23 .9 8 1.4 3 1.5 6 5. 11 0. 17 La va nd ul a an gu sti fo lia (la ve nd er ) 54 .52 94 .14 0. 46 4. 32 0. 10 3. 75 9.6 4 0. 22 3. 42 6. 42 0. 12 75 .76 75 .76 1.8 7 0. 62 16 .8 3 0. 90 3. 55 67 .8 7 1.7 7 Le pt os pe rm um sc op ar iu m (m an uk a) 95 .4 9 98 .8 2 10 .2 4 59 .7 0 1.4 0 4. 17 8. 64 0. 20 5. 37 7.8 1 0. 14 1.3 2 13 .4 6 0. 33 7.0 1 32 .8 5 1.7 5 2. 68 61 .8 0 1.5 9 Li tse a cu be ba (m ay ch an g) 99 .5 8 99 .5 8 4. 37 23 .9 8 0. 56 2. 97 27 .9 7 0. 63 0. 52 5. 51 0. 10 1.2 6 41 .2 6 1 .0 1 0. 58 12 .9 8 0. 69 2. 45 72 .2 2 1.8 6 M ela leu ca al te rn ifo lia (te a tre e) 71 .17 94 .2 0 0. 46 3. 29 0. 08 4. 57 6. 60 0. 15 4. 81 7.3 4 0. 13 10 0. 00 10 0. 00 2. 47 0. 29 6. 74 0. 36 0. 00 15 .8 3 0. 41 M ela leu ca vi rid ifl or a (n ia ou li) 33 .4 3 61 .32 1.0 5 4. 23 0. 11 4. 22 7.8 9 0. 20 3. 66 7.2 1 0. 15 0. 91 3. 57 0. 10 1.1 0 11. 80 0. 66 0. 56 56 .2 8 1.6 3 M eli ssa offi cin al is (le m on ba lm ) 92 .31 96 .2 5 6. 14 15 .9 5 0. 38 2. 59 5. 05 0. 12 6. 15 8. 21 0. 15 5. 93 16 .6 3 0. 41 2. 19 13 .9 3 0. 74 1.1 7 22 .4 0 0. 58 Po go ste m on pa tch ou li (p at ch ou li) 88 .4 9 95 .33 7.7 7 27 .13 0. 64 3. 81 19 .16 0. 44 8. 21 27 .0 7 0. 49 0. 55 7.9 7 0. 20 8. 71 29 .0 2 1.5 5 2. 18 38 .0 5 0. 99 Evidence-Based Complementary and Alternative Medicine 21 Ta bl e 4: C on tin ue d. Es se nt ia lo il Cy to to xi ci ty al on e Al oe ve ra Ca le nd ul a offi ci na lis H yp er icu m pe rf or at um Pe rs ea am er ica na Pr un us ar m en ia ca Si m m on ds ia ch in en sis 24 hr s 48 hr s 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C 24 hr s 48 hr s Σ FI C Sa nt al um al bu m (s an da lw oo d) 96 .12 99 .13 1.5 9 8. 61 0. 20 4. 84 11. 73 0. 27 4. 20 17. 51 0. 31 32 .11 67 .0 0 1.6 4 3. 59 38 .5 6 2. 05 0. 00 32 .6 4 0. 84 St yr ax be nz oi n (b en zo in ) 16 .4 0 68 .6 6 5. 28 8. 98 0. 23 10 .9 1 28 .2 8 0. 70 9.7 3 17. 99 0. 36 13 .17 35 .8 7 0. 96 31 .53 43 .9 9 2. 44 11 .8 4 60 .6 2 1.7 0 Sy zy giu m ar om at icu m (c lo ve ) 98 .8 8 99 .4 6 4. 33 12 .9 7 0. 30 99 .4 2 99 .4 2 2. 25 98 .9 3 98 .9 3 1.7 6 10 0. 00 10 0. 00 2. 44 78 .6 1 10 0. 00 5. 32 4. 20 32 .6 3 0. 84 � ym us vu lga ris (th ym e) 10 0. 00 10 0. 00 86 .32 97 .11 2. 28 54 .6 1 70 .39 1.5 9 99 .4 8 99 .4 8 1.7 6 7.4 9 20 .52 0. 50 84 .6 8 88 .6 3 4. 71 52 .0 0 85 .2 2 2. 19 Ve tiv er ia zi za ni oi de s (v et iv er ) 11 .37 27 .4 3 2. 52 4. 57 0. 17 4. 93 10 .4 5 0. 37 3. 51 8. 50 0. 26 0. 37 98 .9 6 3. 73 0. 62 9.0 5 0. 60 0. 67 7.7 4 0. 30 ∗ Pe rc en ta ge cy to to xi ci ty ab ov e5 0 is co ns id er ed to xi c; be lo w 50 is co ns id er ed no nt ox ic . † sy ne rg y hi gh lig ht ed in bo ld . ‡ an ta go ni sm sh ow n w ith un de rli ne . 22 Evidence-Based Complementary and Alternative Medicine 70% 30% Essential oils alone 13% 87% Hypericum perforatum 13% 87% Persea americana 13% 87% Prunus armeniaca 9% 91% Simmondsia chinensis 22% 78% Calendula officinalis 9% 91% Aloe vera (a) 87% 13% Essential oils alone 13% 87% Aloe vera 26% 74% Calendula officinalis 17% 83% Hypericum perforatum 13% 87% Prunus armeniaca 30% 70% Persea americana 48% 52% Simmondsia chinensis (b) Figure 3: Summary of essential oil cytotoxicity alone and when in combination with each carrier oil (a, decrease in cytotoxicity after 24 hrs; b, decrease of cytotoxicity after 48 hrs). Non-toxic is shown as black and cytotoxic is shown as grey. Figure 3 summarises the percentage of essential oils that were found to be toxic alone and the percentage of toxic essential oils once combined with carrier oils. At 24 hrs (a), 70% of the essential oils were toxic and this decreased to 9-22% once combined with the respective carrier oil. The essential oil cytotoxicity at 48 hrs (b) decreased from 87% down to 13-48% once combined with the respective carrier oil. The carrier oils that decrease the cytotoxicity from the essential oils the most was A. vera and S. chinensis at 24 hrs andA. vera and P. armeniaca at 48 hrs. Overall it can be noted that the carrier oils decreased the cytotoxicity of the essential oils. Several essential oils were found to display high levels of cytotoxicity, with only half or less of the carrier oils decreasing their cytotoxicity. These include Citrus bergamia (bergamot), Cymbopogon citratus (lemongrass), Syzygium aromaticum (clove), and �ymus vulgaris (thyme). Syzygium aromaticum was also previously reported to display cytotoxicity against Evidence-Based Complementary and Alternative Medicine 23 human fibroblasts [24] and only two carrier oils (A. vera and S. chinensis) decreased the cytotoxicity of this oil. Citrus bergamia is known to cause phototoxicity [25] but cytotoxicity could be decreased byP. americana,P. armeniaca, and S. chinensis; and C. citratus and T. vulgaris were also previously reported to display cytotoxicity [26, 27]. �ymus vulgaris cytotoxicity was reduced by P. americana only, and C. citratus essential oil cytotoxicity was minimised byA. vera, H. perforatum, and P. armeniaca. Cymbopogonmartinii (palmarosa) is an essential oil, often recommended for acne, and S. chinensis is the carrier oil used for acne treatment, as previously reviewed [13]; however, the combination of C. martinii with S. chinensis was found to remain toxic at 24 hrs. In practice, smaller quantities of essential oils are blended into larger quantities of carrier oils and it is suggested that the carrier oil blend should consist of only 1-3% of essential oil:carrier oil mix [28]. As the combinations investigated in this study were performed at a 1:1 ratio, it may be possible that the essential oil cytotoxicity would decrease further once diluted into a higher concentration of carrier oils. 4. Conclusion This study can conclude that carrier oils exert a positive effect over essential oil cytotoxicity without causing antagonism of the antimicrobial activity. Synergy was frequently observed and a reduction of essential oil cytotoxicity after 48 hrs was mostly found. Aloe vera and S. chinensis were identified as the carrier oils that caused the highest reduction of cytotoxicity and increased antimicrobial activity the most. Aloe vera, S. chinensis, H. perforatum C. officinalis, and P. americana were found to increase antimicrobial activity of several essential oils against respective pathogens, including B. epidermidis,B. linens, and P. aeruginosa. Additional studies could include different chemotypes as well as the essential oil:carrier oil combinations where carrier oils are used at a higher ratio, especially against the more toxic essential oils. The carrier oils are also presented as an option for use in dermatology to decrease cytotoxicity of medicines that cause skin irritation. Data Availability The data used to support the findings of this study are available from the corresponding author upon request. Conflicts of Interest No conflicts of interest are declared. Acknowledgments The National Research Foundation and the University of the Witwatersrand Financial Research Committee are thanked for financial support. Supplementary Materials Essential oil selection based on popularity and antimicro- bial activity reported in our previous study. (Supplementary Materials) References [1] A. Orchard, M. Sandasi, G. Kamatou, A. Viljoen, and S. van Vuuren, “The in vitro antimicrobial activity and chemometric modelling of 59 commercial essential oils against pathogens of dermatological relevance,”Chemistry & Biodiversity, vol. 14, no. 1, 2017. [2] A. Orchard, S. F. van Vuuren, A. Viljoen, and G. Kamatou, “The in vitro antimicrobial evaluation of commercial essential oils and their combinations against acne,” International Journal of Cosmetic Science, vol. 40, no. 3, pp. 226–243, 2018. [3] M. Lahlou, “Methods to study the phytochemistry and bioac- tivity of essential oils,” Phytotherapy Research, vol. 18, no. 6, pp. 435–448, 2004. [4] A. Trattner, M. David, and A. Lazarov, “Occupational contact dermatitis due to essential oils,” Contact Dermatitis, vol. 58, no. 5, pp. 282–284, 2008. [5] J. Harding,�eEssential Oils Handbook, DuncanBaird Publish- ers, London, UK, 2008. [6] A. Tadele, K. Urga, N. Gemeda, H. Lemma, D. Melaku, and K. Mudie, “Antimicrobial activity of topical formulations contain- ing �ymus vulgaris essential oil on major pathogens causing skin diseases,” Ethiopian Pharmaceutical Journal, vol. 26, no. 2, 2009. [7] A. Orchard, S. van, and Vuuren., “Carrier oils in dermatology,” Archives of Dermatological Research, 2018. [8] J. Salimon, T. A. Omar, and N. Salih, “An accurate and reliable method for identification and quantification of fatty acids and trans fatty acids in food fats samples using gas chromatography,” Arabian Journal of Chemistry, vol. 10, pp. S1875–S1882, 2017. [9] G. P. P. Kamatou and A. M. Viljoen, “Comparison of fatty acid methyl esters of palm and palmist oils determined by GCxGC–ToF–MS and GC–MS/FID,” South African Journal of Botany, vol. 112, pp. 483–488, 2017. [10] S. van Vuuren and A. Viljoen, “Plant-based antimicrobial studies—methods and approaches to study the interaction between natural products,” Planta Medica, vol. 77, no. 11, pp. 1168–1182, 2011. [11] I. E. Cock and F. R. Kalt, “Toxicity evaluation of Xanthorrhoea johnsonii leaf methanolic extract using the Artemia franciscana bioassay,” Pharmacognosy Magazine, vol. 6, no. 23, pp. 166–171, 2010. [12] R. W. Bussmann, G. Malca, A. Glenn et al., “Toxicity of medicinal plants used in traditional medicine in Northern Peru,” Journal of Ethnopharmacology, vol. 137, no. 1, pp. 121–140, 2011. [13] A. Orchard and S. Van Vuuren, “Commercial essential oils as potential antimicrobials to treat skin diseases,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 4517971, 92 pages, 2017. [14] K. Thu, Y. Y. Mon, T. A. Khaing, and O. M. Tun, “Study on phytochemical properties, antibacterial activity and cytotoxic- ity of Aloe vera L,” World Academy of Science, Engineering and Technology, vol. 7, no. 5, pp. 114–118, 2013. http://downloads.hindawi.com/journals/ecam/2019/6981305.f1.docx http://downloads.hindawi.com/journals/ecam/2019/6981305.f1.docx 24 Evidence-Based Complementary and Alternative Medicine [15] J. T. Lyles, A. Kim, K. Nelson et al., “The chemical and antibacterial evaluation of St. John’s Wort oil macerates used in Kosovar traditional medicine,” Frontiers in Microbiology, vol. 8, 2017. [16] A. P. Desbois and K. C. Lawlor, “Antibacterial activity of long- chain polyunsaturated fatty acids against Propionibacterium acnes and Staphylococcus aureus,” Marine Drugs, vol. 11, no. 11, pp. 4544–4557, 2013. [17] A. Yaron, A. Benzioni, and I. More, “Absorption and distribu- tion of jojoba wax injected subcutaneously into mice,” Lipids, vol. 15, no. 11, pp. 889–894, 1980. [18] L. Cole and C. Heard, “Skin permeation enhancement potential of Aloe Vera and a proposed mechanism of action based upon size exclusion and pull effect,” International Journal of Pharmaceutics, vol. 333, no. 1-2, pp. 10–16, 2007. [19] C. H. Okuma, T. A. M. Andrade, G. F. Caetano et al., “Devel- opment of lamellar gel phase emulsion containing marigold oil (Calendula officinalis) as a potential modern wound dressing,” European Journal of Pharmaceutical Sciences, vol. 71, pp. 62–72, 2015. [20] J.-R. Kim, P. Haribalan, B.-K. Son, and Y.-J. Ahn, “Fumigant toxicity of plant essential oils against camptomyia corticalis (diptera: Cecidomyiidae),” Journal of Economic Entomology, vol. 105, no. 4, pp. 1329–1334, 2012. [21] K. De Prijck, E. Peeters, and H. J. Nelis, “Comparison of solid- phase cytometry and the plate count method for the evaluation of the survival of bacteria in pharmaceutical oils,” Letters in Applied Microbiology, vol. 47, no. 6, pp. 571–573, 2008. [22] I. Meral, B. Baydaş, F. Bayiroǧlu, and H. Uysal, “Role of vitamin E in decreasing the toxic effect of digoxin,” Turkish Journal of Veterinary andAnimal Sciences, vol. 23, no. 5, pp. 445–450, 1999. [23] C.-F. Hung, C.-L. Fang, M.-H. Liao, and J.-Y. Fang, “The effect of oil components on the physicochemical properties and drug delivery of emulsions: tocol emulsion versus lipid emulsion,” International Journal of Pharmaceutics, vol. 335, no. 1-2, pp. 193– 202, 2007. [24] A. Prashar, I. C. Locke, and C. S. Evans, “Cytotoxicity of clove (Syzygium aromaticum) oil and itsmajor components to human skin cells,” Cell Proliferation, vol. 39, no. 4, pp. 241–248, 2006. [25] K. Kejlová, D. J́ırová, H. Bendová et al., “Phototoxicity of bergamot oil assessed by in vitro techniques in combination with human patch tests,” Toxicology in Vitro, vol. 21, no. 7, pp. 1298–1303, 2007. [26] R. Khosravi and J. J. Sendi, “Toxicity, development and phys- iological effect of �ymus vulgaris and Lavandula angus- tifolia essential oils on Xanthogaleruca luteola (Coleoptera: Chrysomelidae),” Journal of King Saud University - Science, vol. 25, no. 4, pp. 349–355, 2013. [27] F. Fuentes-León,M. González-Pumariega, M. Vernhes Tamayo, C. Menck, and Á. Sánchez-Lamar, “Toxic evaluation of Cymbo- pogon citratus chemical fractions in E. coli,” Cosmetics, vol. 4, no. 2, p. 20, 2017. [28] J. Lawless, �e Illustrated Encyclopedia of Essential Oils: �e Complete Guide to the Use of Oils in Aromatherapy and Herbal- ism, Element books, Massachusetts, USA, 1995. Stem Cells International Hindawi www.hindawi.com Volume 2018 Hindawi www.hindawi.com Volume 2018 MEDIATORS INFLAMMATION of Endocrinology International Journal of Hindawi www.hindawi.com Volume 2018 Hindawi www.hindawi.com Volume 2018 Disease Markers Hindawi www.hindawi.com Volume 2018 BioMed Research International Oncology Journal of Hindawi www.hindawi.com Volume 2013 Hindawi www.hindawi.com Volume 2018 Oxidative Medicine and Cellular Longevity Hindawi www.hindawi.com Volume 2018 PPAR Research Hindawi Publishing Corporation http://www.hindawi.com Volume 2013 Hindawi www.hindawi.com The Scientific World Journal Volume 2018 Immunology Research Hindawi www.hindawi.com Volume 2018 Journal of Obesity Journal of Hindawi www.hindawi.com Volume 2018 Hindawi www.hindawi.com Volume 2018 Computational and Mathematical Methods in Medicine Hindawi www.hindawi.com Volume 2018 Behavioural Neurology Ophthalmology Journal of Hindawi www.hindawi.com Volume 2018 Diabetes Research Journal of Hindawi www.hindawi.com Volume 2018 Hindawi www.hindawi.com Volume 2018 Research and Treatment AIDS Hindawi www.hindawi.com Volume 2018 Gastroenterology Research and Practice Hindawi www.hindawi.com Volume 2018 Parkinson’s Disease Evidence-Based Complementary and Alternative Medicine Volume 2018 Hindawi www.hindawi.com Submit your manuscripts at www.hindawi.com https://www.hindawi.com/journals/sci/ https://www.hindawi.com/journals/mi/ https://www.hindawi.com/journals/ije/ https://www.hindawi.com/journals/dm/ https://www.hindawi.com/journals/bmri/ https://www.hindawi.com/journals/jo/ https://www.hindawi.com/journals/omcl/ https://www.hindawi.com/journals/ppar/ https://www.hindawi.com/journals/tswj/ https://www.hindawi.com/journals/jir/ https://www.hindawi.com/journals/jobe/ https://www.hindawi.com/journals/cmmm/ https://www.hindawi.com/journals/bn/ https://www.hindawi.com/journals/joph/ https://www.hindawi.com/journals/jdr/ https://www.hindawi.com/journals/art/ https://www.hindawi.com/journals/grp/ https://www.hindawi.com/journals/pd/ https://www.hindawi.com/journals/ecam/ https://www.hindawi.com/ https://www.hindawi.com/